{ "_id" : { "$oid" : "55897f2c60b24f0590ca8974" }, "standardHeader" : { "uuid" : "05e4c338-f2a9-4e5b-87cf-4789ccac4e40", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-609-2013", "openfda" : { "pharm_class_cs" : [ [ "Lincosamides [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Lincosamide Antibacterial [EPC]" ] ], "nui" : [ [ "N0000009982", "N0000175442", "N0000175443" ] ], "manufacturer_name" : [ [ "Pharmacia and Upjohn Company" ] ], "application_number" : [ [ "NDA050441" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "CLEOCIN PHOSPHATE" ] ], "route" : [ [ "INTRAMUSCULAR", "INTRAVENOUS" ] ], "substance_name" : [ [ "CLINDAMYCIN PHOSPHATE" ] ], "rxcui" : [ [ "685576", "685574", "205964", "706461", "685578", "309336", "309335", "309339" ] ], "pharm_class_pe" : [ [ "Decreased Sebaceous Gland Activity [PE]" ] ], "package_ndc" : [ [ "0009-3375-02", "0009-0728-05", "0009-3375-01", "0009-0728-09", "0009-0775-26", "0009-3381-02", "0009-0775-20", "0009-3382-01", "0009-3124-01", "0009-0902-18", "0009-3124-03", "0009-0870-21", "0009-0870-26", "0009-3382-02", "0009-3447-03", "0009-0902-11", "0009-3447-01", "0009-3381-01" ] ], "generic_name" : [ [ "CLINDAMYCIN PHOSPHATE" ] ], "spl_id" : [ [ "a5785df9-aedf-4fcc-9f48-4ff0490e52db" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0009-0775", "0009-3124", "0009-0728", "0009-0902", "0009-0870", "0009-3381", "0009-3382", "0009-3375", "0009-3447" ] ], "spl_set_id" : [ [ "05a75685-0af5-407c-ac57-e380c882b49d" ] ], "unii" : [ [ "3U02EL437C" ] ] }, "product_quantity" : "898,900 Vials", "state" : "MI", "recall_initiation_date" : "20130604", "event_id" : "65275", "product_description" : "Cleocin Phosphate (clindamycin Injection), USP, a) 600 mg/4mL (150 mg/mL) ADD-Vantage Vial, b) 900 mg/6mL (150 mg/mL) ADD-Vantage Vial, Rx Only, For Intravenous Use Only, Use Only with the ADD-Vantage diluent container, Distributed by Pharmacia & Upjohn Co, Division of Pfizer Inc, NY, NY 10017, NDC a) 0009-3124-03 and b) 0009-3447-03", "recalling_firm" : "Pharmacia & Upjohn LLC", "city" : "Kalamazoo", "@epoch" : 1424553174.836488, "code_info" : "Lots: a) G34908, Exp 06/14; G53479, Exp 09/14; G63442, G58347, Exp 10/14; G80133, Exp 12/14; and b) G34910, Exp 06/14; G36879, G41005, Exp 07/14; G53478, Exp 09/14; G63444, Exp 10/14; G76317, Exp 11/14.", "reason_for_recall" : "Presence of Particulate Matter: Firm is recalling a small number of vials with very small reflective flakes consistent with delamination of the glass vial.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130626", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "00171f18d8cb43cc762010ec99a8636631470e6bee678b7decbfd9a1789425af", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8975" }, "standardHeader" : { "uuid" : "c11e421b-b758-4f48-aa72-17b6d64b561e", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-928-2013", "openfda" : { "pharm_class_cs" : [ [ "Platinum-containing Compounds [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Platinum-based Drug [EPC]" ] ], "nui" : [ [ "N0000175073", "N0000175413" ] ], "manufacturer_name" : [ [ "Teva Parenteral Medicines, Inc." ] ], "application_number" : [ [ "ANDA077139" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "CARBOPLATIN" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "CARBOPLATIN" ] ], "rxcui" : [ [ "597195" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0703-3249-11" ] ], "generic_name" : [ [ "CARBOPLATIN" ] ], "spl_id" : [ [ "670b25ff-ff6d-4311-8750-ad462eae168d" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0703-3249" ] ], "spl_set_id" : [ [ "bdb0b6dd-91d3-4896-be6e-313ea907d8bb" ] ], "unii" : [ [ "BG3F62OND5" ] ] }, "product_quantity" : "780 vials", "state" : "PA", "recall_initiation_date" : "20130813", "event_id" : "65959", "product_description" : "CARBOplatin Injection, 600 mg/60ml, MultiDose, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618 NDC 0703-3249-11", "recalling_firm" : "Teva Pharmaceuticals USA, Inc.", "city" : "Sellersville", "@epoch" : 1424553174.836488, "code_info" : "Lot  31314458B, 31314459B exp.08/14,  31315794 exp. 10/14, 31315982B exp.11/14", "reason_for_recall" : "Lack of Assurance of Sterility: The required reduction of endotoxin was not met during the annual revalidation of the vial washer.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130911", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "006c6806db9eea98840bd56c54e7c96366fe8e0c3502e14e923deeabd79c643b", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8976" }, "standardHeader" : { "uuid" : "e007fa2a-2892-4910-a4e1-0eb3bd1cf3e5", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1166-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Histamine-1 Receptor Antagonist [EPC]" ] ], "nui" : [ [ "N0000175587", "N0000000190" ] ], "manufacturer_name" : [ [ "Pfizer Consumer Healthcare" ] ], "application_number" : [ [ "NDA021394" ] ], "product_type" : [ [ "HUMAN OTC DRUG" ] ], "brand_name" : [ [ "ADVIL PM" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "DIPHENHYDRAMINE CITRATE", "IBUPROFEN" ] ], "rxcui" : [ [ "895664", "901818" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0573-0164-04", "0573-0164-05", "0573-0164-20", "0573-0164-21", "0573-0164-12", "0573-0164-45", "0573-0164-55", "0573-0164-14", "0573-0164-91", "0573-0164-40", "0573-0164-41", "0573-0164-43", "0573-0164-44", "0573-0164-30", "0573-0164-33", "0573-0164-32" ] ], "generic_name" : [ [ "DIPHENHYDRAMINE CITRATE AND IBUPROFEN" ] ], "spl_id" : [ [ "8a1758ee-95d6-4a8b-bf7f-819c8132aad2" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Histamine H1 Receptor Antagonists [MoA]" ] ], "product_ndc" : [ [ "0573-0164" ] ], "spl_set_id" : [ [ "658fc201-47c9-6a6d-8af9-6208298d43b4" ] ], "unii" : [ [ "8GTS82S83M" ] ] }, "product_quantity" : "70,704 bottles", "state" : "NY", "recall_initiation_date" : "20140226", "event_id" : "67617", "product_description" : "Advil PM Caplets, (Ibuprofen, 200 mg /Diphenhydramine citrate, 38 mg) 120 count bottle, OTC, Pfizer, Madison, NJ 07940 USA. NDC 0573-0164-43", "recalling_firm" : "Pfizer Us Pharmaceutical Group", "city" : "New York", "@epoch" : 1424553174.836488, "code_info" : "G85041", "reason_for_recall" : "Subpotent Drug: This lot is being recalled because of out-of-specification test results for Diphenhydramine citrate.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140326", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "00b452d9f4f882d963763d8042f8f360e4c5e4b97d1c6fba00e1d04801c0d136", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8977" }, "standardHeader" : { "uuid" : "896ef464-224e-4c54-86f0-3333822cc0a2", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0969-2015", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [], "nui" : [], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "NDA018090" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "SODIUM CHLORIDE" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "SODIUM CHLORIDE" ] ], "rxcui" : [ [ "313002", "237372" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0409-7983-61", "0409-7983-09", "0409-7984-20", "0409-7983-02", "0409-7983-03", "0409-7984-23", "0409-7985-02", "0409-7985-03", "0409-7730-20", "0409-7984-36", "0409-7984-13", "0409-7730-37", "0409-7730-36", "0409-7984-37", "0409-7983-53", "0409-7983-55", "0409-7985-09" ] ], "generic_name" : [ [ "SODIUM CHLORIDE" ] ], "spl_id" : [ [ "5cfe5cca-4976-44bd-b091-3365da10adef" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0409-7983", "0409-7730", "0409-7985", "0409-7984" ] ], "spl_set_id" : [ [ "089fc1de-00ae-41b6-7c97-1217f0cecc03" ] ], "unii" : [] }, "product_quantity" : "661,128 containers", "state" : "IL", "recall_initiation_date" : "20150120", "event_id" : "70303", "product_description" : "0.9% Sodium Chloride Injection, USP, 250 mL, Rx Only, Hospira Inc., Lake Forest, IL, 60045, USA, NDC 0409-7983-02", "recalling_firm" : "Hospira Inc.", "city" : "Lake Forest", "@epoch" : 1430515130.085608, "code_info" : "Lot #: 44-002-JT (the lot number may be followed by 01 to 99), Exp 08/01/2016", "reason_for_recall" : "Presence of Particulate Matter; Hospira has identified the particulate as a human hair, sealed in the bag at the additive port area.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20150429", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class I", "@id" : "00e52dcc5d9c491554c26c9fbbfb23ad2aadc2f5856b0dc903125549d9e6c004", "initial_firm_notification" : "Press Release", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8978" }, "standardHeader" : { "uuid" : "4f4d6d38-72a6-4ebc-9ff3-f72099e59bef", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-527-2013", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Sigma-1 Agonist [EPC]", "Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC]" ] ], "nui" : [ [ "N0000181821", "N0000181819", "N0000182149", "N0000182147" ] ], "manufacturer_name" : [ [ "MCR American Pharmaceuticals, Inc." ] ], "application_number" : [ [ "part341" ] ], "product_type" : [ [ "HUMAN OTC DRUG" ] ], "brand_name" : [ [ "BROVEX PSB DM" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "BROMPHENIRAMINE MALEATE", "PSEUDOEPHEDRINE HYDROCHLORIDE", "DEXTROMETHORPHAN HYDROBROMIDE" ] ], "rxcui" : [ [ "1356840", "1356838" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "58605-151-02", "58605-151-01" ] ], "generic_name" : [ [ "PSEUDOEPHEDRINE HYDROCHLORIDE, BROMPHENIRAMINE MALEATE, AND DEXTROMETHORPHAN HYDROBROMIDE" ] ], "spl_id" : [ [ "b652e5a8-f339-4e39-b410-9e0857ffba3a" ] ], "upc" : [ [ "0358605151017" ] ], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Uncompetitive NMDA Receptor Antagonists [MoA]", "Sigma-1 Receptor Agonists [MoA]" ] ], "product_ndc" : [ [ "58605-151" ] ], "spl_set_id" : [ [ "5a6f21f8-651f-4559-98d8-bb2646a216ca" ] ], "unii" : [ [ "7355X3ROTS" ] ] }, "product_quantity" : "19,728 bottles - 20 mL and 20,016 bottles - 16 ounce.", "state" : "FL", "recall_initiation_date" : "20130130", "event_id" : "64188", "product_description" : "BroveX PSB DM LIQUID, Antihistamine, Decongestant, a) 16 fl oz. bottle, OTC, NDC 58605-151-01  b) 20 ml NDC 58605-151-02,  Manufactured for: Pernix Therapeutics, Gonzales, LA 70737", "recalling_firm" : "TG United, Inc.", "city" : "Brooksville", "@epoch" : 1424553174.836488, "code_info" : "Lot# 11AQ004  Exp. 12/12; Lot# 11AQ005  Exp. 12/12; Lot # 11AQ006  Exp. 12/12; Lot# 11AQ007  Exp. 12/12; Lot # 11BQ012  Exp. 01/13; Lot# 11LQ003  Exp. 10/13; Lot# 11LQ004  Exp. 10/13; Lot# 11LQ005 Exp 10/13; Lot# 11LQ006 Exp. 10/2013.", "reason_for_recall" : "CGMP Deviations: Products are underdosed or have an incorrect dosage regime.", "distribution_pattern" : "FL, MS, SC, LA  and TX", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130612", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "00ffe37ba227e2c20e7a563ae99ac82e615007bd410246a48a3057f995278768", "initial_firm_notification" : "Letter", "recall_area" : [ "Florida", "Louisiana", "Mississippi", "South Carolina", "Texas" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8979" }, "standardHeader" : { "uuid" : "b0d103f5-9103-4cd5-a5c2-d6cdb7d9bc87", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0413-2015", "openfda" : { "pharm_class_cs" : [ [ "Dihydropyridines [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Dihydropyridine Calcium Channel Blocker [EPC]" ] ], "nui" : [ [ "N0000175421", "N0000007556", "N0000000069" ] ], "manufacturer_name" : [ [ "Mylan Institutional LLC" ] ], "application_number" : [ [ "ANDA090664" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "NICARDIPINE HYDROCHLORIDE" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "NICARDIPINE HYDROCHLORIDE" ] ], "rxcui" : [ [ "858607" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "67457-224-10", "67457-224-00" ] ], "generic_name" : [ [ "NICARDIPINE HYDROCHLORIDE" ] ], "spl_id" : [ [ "ce2304e0-b9fd-4612-96b0-ef611a71cd4e" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Calcium Channel Antagonists [MoA]" ] ], "product_ndc" : [ [ "67457-224" ] ], "spl_set_id" : [ [ "0a7c6372-a22b-4501-a6c6-539457a6cd9d" ] ], "unii" : [ [ "CZ5312222S" ] ] }, "product_quantity" : "78,090 vials", "state" : "IL", "recall_initiation_date" : "20150123", "event_id" : "70375", "product_description" : "Nicardipine Hydrochloride Injection, 25 mg/10 ml (2.5 mg/mL),10 mL single dose vial, Rx only, Manufactured in India for: Mylan Institutional LLC, Rockford, IL 61103, NDC 67457-224-10", "recalling_firm" : "Mylan Institutional LLC", "city" : "Rockford", "@epoch" : 1428088411.295797, "code_info" : "Lot #: UW301, UW302, Exp 02/15; UW303, UW304, UW305, UW306, Exp 04/15", "reason_for_recall" : "Subpotent Drug and Failed Impurities/Degradation Specifications.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20150325", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "0107ec1b21d9128e0ec27655f7a50aeade85fd66da524f6d5aca6674151004e5", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca897a" }, "standardHeader" : { "uuid" : "c32a3b3d-ebb6-4a31-b8c6-2bef7c2dacba", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-202-2013", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Serotonin and Norepinephrine Reuptake Inhibitor [EPC]" ] ], "nui" : [ [ "N0000175749", "N0000000109", "N0000000102" ] ], "manufacturer_name" : [ [ "Zydus Pharmaceuticals (USA) Inc." ] ], "application_number" : [ [ "ANDA077653" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "VENLAFAXINE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "VENLAFAXINE HYDROCHLORIDE" ] ], "rxcui" : [ [ "313582", "313580", "313586", "314277", "313584" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "68382-019-06", "68382-019-05", "68382-018-05", "68382-018-06", "68382-018-01", "68382-020-01", "68382-020-06", "68382-020-05", "68382-019-01", "68382-101-01", "68382-021-05", "68382-021-06", "68382-101-05", "68382-021-01", "68382-101-06", "68382-019-14", "68382-019-16", "68382-018-10", "68382-019-10", "68382-018-16", "68382-018-14", "68382-020-10", "68382-020-14", "68382-020-16", "68382-101-16", "68382-021-16", "68382-101-14", "68382-021-14", "68382-101-10", "68382-021-10" ] ], "generic_name" : [ [ "VENLAFAXINE" ] ], "spl_id" : [ [ "de566363-6eed-4877-b796-fbafcf5a6bfa" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Norepinephrine Uptake Inhibitors [MoA]", "Serotonin Uptake Inhibitors [MoA]" ] ], "product_ndc" : [ [ "68382-101", "68382-018", "68382-019", "68382-021", "68382-020" ] ], "spl_set_id" : [ [ "72efad5f-0909-46a5-aa13-ac24fe015fe6" ] ], "unii" : [ [ "GRZ5RCB1QG" ] ] }, "product_quantity" : "13,320 bottles", "state" : "NJ", "recall_initiation_date" : "20130305", "event_id" : "64604", "product_description" : "Venlafaxine Hydrochloride Tablets, 75 mg*, 100-count tablets per bottle, Rx only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India; Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-021-01.", "recalling_firm" : "Zydus Pharmaceuticals USA Inc", "city" : "Pennington", "@epoch" : 1424553174.836488, "code_info" : "Lot #: MM8490, Exp 09/14", "reason_for_recall" : "Failed Tablet/Capsule Specifications: Pharmacist complaint of an excessive amount of broken and/or chipped tablets in the bottle.", "distribution_pattern" : "Nationwide.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130403", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "01141c6878711ac03d4d3ef95a7c55236cb5d1b013cda827ea561238733a567b", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca897b" }, "standardHeader" : { "uuid" : "5e8c03c0-3c58-450d-93a5-37588a3f0a9d", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1646-2012", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Corticosteroid [EPC]" ] ], "nui" : [ [ "N0000175576", "N0000175450" ] ], "manufacturer_name" : [ [ "Hill Dermaceuticals, Inc." ] ], "application_number" : [ [ "NDA019452" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "DERMA-SMOOTHE/FS" ] ], "route" : [ [ "TOPICAL" ] ], "substance_name" : [ [ "FLUOCINOLONE ACETONIDE" ] ], "rxcui" : [ [ "1191309", "1191307" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "28105-149-04" ] ], "generic_name" : [ [ "FLUOCINOLONE ACETONIDE" ] ], "spl_id" : [ [ "19741b55-154b-4182-a408-1a2e312269aa" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Corticosteroid Hormone Receptor Agonists [MoA]" ] ], "product_ndc" : [ [ "28105-149" ] ], "spl_set_id" : [ [ "ab72c8d6-704a-4707-a7f8-0cb70f3ff093" ] ], "unii" : [ [ "0CD5FD6S2M" ] ] }, "product_quantity" : "161,064 bottles", "state" : "FL", "recall_initiation_date" : "20120508", "event_id" : "62607", "product_description" : "Derma-Smoothe/FS (Fluocinolone Acetonide) 0.01% Topical Oil (Scalp Oil), 4 fl oz (118.28mL) bottle, Rx only, FOR TOPICAL USE ONLY NOT, Manufactured and Distributed by: Hill Dermaceuticals, Inc. SANFORD, FLORIDA ---  NDC 28105-149-04", "recalling_firm" : "Hill Dermaceuticals, Inc.", "city" : "Sanford", "@epoch" : 1424553174.836488, "code_info" : "Lot Numbers: \n-Scalp Oil: H100084 (exp 08/12), H100086 (08/12), J100093 (exp 08/12), J100094 (exp 09/12), J100097 (exp 09/12), K100101 (exp 09/12), K100103 (exp 10/12), K100104 (exp 10/12), K100108 (exp 10/12), K100112 (exp 10/12), L100860 (exp 11/12), L100890 (exp 11/12), L100910 (exp 11/12).", "reason_for_recall" : "Subpotent; fluocinolone acetonide", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20120822", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "01319f8e4eee9192f1253f3747ae9664e1b764a7d6eccb144f945998688c8308", "initial_firm_notification" : "Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca897c" }, "standardHeader" : { "uuid" : "6bd7ea5a-d7f1-48ff-bb23-e1284b0fe904", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0482-2015", "openfda" : { "pharm_class_cs" : [ [ "Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Nonsteroidal Anti-inflammatory Drug [EPC]" ] ], "nui" : [ [ "N0000000160", "N0000175722", "N0000175721" ] ], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "ANDA074802" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "KETOROLAC TROMETHAMINE" ] ], "route" : [ [ "INTRAMUSCULAR", "INTRAVENOUS" ] ], "substance_name" : [ [ "KETOROLAC TROMETHAMINE" ] ], "rxcui" : [ [ "860096", "860092" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0409-3796-49", "0409-3793-01", "0409-3795-01", "0409-3793-49", "0409-3795-49", "0409-3796-01" ] ], "generic_name" : [ [ "KETOROLAC TROMETHAMINE" ] ], "spl_id" : [ [ "0084370a-8793-4cb8-bbc9-d58a8a345b86", "0c5de268-3945-429c-9c3b-69dfb19344c1" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Cyclooxygenase Inhibitors [MoA]" ] ], "product_ndc" : [ [ "0409-3793", "0409-3796", "0409-3795" ] ], "spl_set_id" : [ [ "6a77b694-e9a7-417d-b9cc-e700771b6728", "8accbb78-fc64-45d5-69b0-35c23a1d2a2e" ] ], "unii" : [ [ "YZI5105V0L" ] ] }, "product_quantity" : "HOSPIRA = 13,720,475 vials, NOVAPLUS = 1,528,500 vials", "state" : "IL", "recall_initiation_date" : "20150123", "event_id" : "70515", "product_description" : "KETOROLAC Tromethamine Inj., USP, 30 mg (30 mg/mL), 1 mL Fill, Single-dose Vials, I.V/I.M. USE, Hospira, Inc., Lake Forest, IL 60045 --- NDC 0409-3795-01 --- Also labeled under NOVAPLUS label NDC 0409-3795-49", "recalling_firm" : "Hospira Inc.", "city" : "Lake Forest", "@epoch" : 1429310080.242206, "code_info" : "NDC 0409-3795-01,\n Lot number: 25-047-DK, 25-048-DK, Exp 1JAN2015;\n Lot number 26-151-DK, Exp. Date:1FEB2015;\n Lot number: 28-059-DK, 28-071-DK, 28-072-DK, 28-479-DK, 28-480-DK, Exp. Date:1APR2015;\n Lot number: 29-556-DK, 29-557-DK, Exp. Date:1MAY2015;\n Lot number: 35-232-DK, 35-233-DK, 35-234-DK, 35-501-DK, Exp. Date:1NOV2015;\n Lot number: 36-341-DK, 36-342-DK, 36-343-DK, 36-353-DK, 36-429-DK, 36-430-DK, Exp. Date:1DEC2015;\n Lot number: 37-141-DK, 37-142-DK, 37-144-DK, 37-145-DK, 37-353-DK, Exp. Date:1JAN2016;\n Lot number: 38-141-DK, 38-143-DK, Exp. Date:1FEB2016;\n Lot number: 39-014-DK, 39-104-DK, Exp. Date:1MAR2016;\n Lot number: 40-301-DK, 40-536-DK, 40-537-DK, 40-544-DK, 40-548-DK, Exp. Date:1APR2016;\n Lot number: 41-078-DK, Exp. Date:1MAY2016;\n Lot number: 42-207-DK, 42-253-DK, Exp. Date:1JUN2016;\n Lot number: 45-358-DK, 45-359-DK, Exp. Date:1SEP2016;\n Lot number: 46-043-DK, 46-044-DK, 46-047-DK, Exp. Date:1OCT2016\n\nAND NOVAPLUS LABEL \nNDC 0409-3795-49,\n Lot number: 27-101-DK, Exp. Date:1MAR2015;\n Lot number: 35-229-DK, Exp. Date:1NOV2015;\n Lot number: 36-217-DK, 36-218-DK, Exp. Date:1DEC2015 and\n Lot number: 40-534-DK, Exp. Date:1APR2016", "reason_for_recall" : "Crystallization", "distribution_pattern" : "U.S. Nationwide and International: Guam and Singapore.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20150415", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "01b37851c0dc49e7bd4109a8a1bed1eb3996f89cbcb5c3a2c3426a5f5e774d65", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca897d" }, "standardHeader" : { "uuid" : "74b0382e-7a5f-4627-8383-a8fdc328a05b", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0411-2015", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Sigma-1 Agonist [EPC]", "Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC]" ] ], "nui" : [ [ "N0000181821", "N0000181819", "N0000182149", "N0000182147" ] ], "manufacturer_name" : [ [ "Qualitest Pharmaceuticals" ] ], "application_number" : [ [ "ANDA040649" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "PROMETHAZINE DM" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "PROMETHAZINE HYDROCHLORIDE", "DEXTROMETHORPHAN HYDROBROMIDE" ] ], "rxcui" : [ [ "991528" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0603-1586-54", "0603-1586-56", "0603-1586-58", "0000001099" ] ], "generic_name" : [ [ "DEXTROMETHORPHAN HYDROBROMIDE AND PROMETHAZINE HYDROCHLORIDE" ] ], "spl_id" : [ [ "86b0bf88-3c6e-4dae-9a97-21be6494e382" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Uncompetitive NMDA Receptor Antagonists [MoA]", "Sigma-1 Receptor Agonists [MoA]" ] ], "product_ndc" : [ [ "0603-1586" ] ], "spl_set_id" : [ [ "c13f5f93-d291-4d0d-80fe-44dba4c5401e" ] ], "unii" : [ [ "7355X3ROTS" ] ] }, "product_quantity" : "972 bottles", "state" : "AL", "recall_initiation_date" : "20150223", "event_id" : "70598", "product_description" : "PROMETHAZINE DM SYRUP (Promethazine Hydrochloride, USP and Dextromethorphan Hydrobromide, USP), EACH 5 ml (ONE TEASPOONFUL) CONTAINS:  Promethazine Hydrochloride 6.25 mg, Dextromethorphan Hydrobromide 15 mg, alcohol 7%,  ONE PINT (574 mL), Rx only, Manufactured for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC:  0603-1586-58.", "recalling_firm" : "Qualitest Pharmaceuticals", "city" : "Huntsville", "@epoch" : 1428088411.295797, "code_info" : "Lot #:  0000001099; Exp. 03/16", "reason_for_recall" : "Presence of Foriegn Substance: Plastic cap closure particulates may be present in the product.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20150318", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "027fcaf9d0deb61b7f1333bfd3295468a8d06f0cc3732e02403caa0fca5e1cec", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca897e" }, "standardHeader" : { "uuid" : "e48de32a-491c-4d56-b473-6bd8dd6225e1", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1417-2012", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Antihistamine [EPC]" ] ], "nui" : [ [ "N0000000207", "N0000175750" ] ], "manufacturer_name" : [ [ "Qualitest Pharmaceuticals" ] ], "application_number" : [ [ "ANDA040391" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "HYDROXYZINE HYDROCHLORIDE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "HYDROXYZINE HYDROCHLORIDE" ] ], "rxcui" : [ [ "995241" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0603-1310-58" ] ], "generic_name" : [ [ "HYDROXYZINE HYDROCHLORIDE" ] ], "spl_id" : [ [ "dbca5110-4c62-4b65-85ad-e79c7c5d0e56" ] ], "upc" : [ [ "306031310584" ] ], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Histamine Receptor Antagonists [MoA]" ] ], "product_ndc" : [ [ "0603-1310" ] ], "spl_set_id" : [ [ "7bcab9cd-2ed9-48c1-b2f5-953ec522e4fc" ] ], "unii" : [ [ "30S50YM8OG" ] ] }, "product_quantity" : "73,746 bottles", "state" : "AL", "recall_initiation_date" : "20120706", "event_id" : "62495", "product_description" : "HYDROXYZINE HYDROCHLORIDE ORAL SOLUTION, USP, 10 mg/5 mL, 1 PINT (473 mL) bottle, Rx only, Mfg. for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-1310-58, UPC 3 0603-1310-58 4.", "recalling_firm" : "Vintage Pharmaceuticals LLC DBA Qualitest Pharmaceuticals", "city" : "Huntsville", "@epoch" : 1424553174.836488, "code_info" : "Lot #s: L030F11A, L054F11A, Exp 05/13; L095E10A, Exp 06/13; L079J10A, L085K11A, L086K11A, L087G10A, L087K11A, L088K11A, Exp 10/13; L094L10A, Exp 12/13; and L100L10B, Exp 01/14", "reason_for_recall" : "Impurities/Degradation Products: High Out of Specification results for a known impurity resulted at the 12-month room temperature time point.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20120725", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "02a4051841bb8d47aea78cf78abd6c9a4b90400a4c10564a50b4fca6a59d2846", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca897f" }, "standardHeader" : { "uuid" : "dc3dbac3-b5a9-4e61-90bc-012c586b990b", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1437-2012", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Anti-epileptic Agent [EPC]" ] ], "nui" : [ [ "N0000175753", "N0000008486" ] ], "manufacturer_name" : [ [ "West-ward Pharmaceutical Corp" ] ], "application_number" : [ [ "ANDA078765" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "FOSPHENYTOIN SODIUM" ] ], "route" : [ [ "INTRAMUSCULAR", "INTRAVENOUS" ] ], "substance_name" : [ [ "FOSPHENYTOIN SODIUM" ] ], "rxcui" : [ [ "855893" ] ], "pharm_class_pe" : [ [ "Decreased Central Nervous System Disorganized Electrical Activity [PE]" ] ], "package_ndc" : [ [ "0143-9788-25", "0143-9782-10", "0143-9704-25" ] ], "generic_name" : [ [ "FOSPHENYTOIN SODIUM" ] ], "spl_id" : [ [ "4306f506-de2f-42e7-a0b6-5a1eb1d481c2" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0143-9782", "0143-9788" ] ], "spl_set_id" : [ [ "c92df63b-5140-4213-8d43-8327ff6230b7" ] ], "unii" : [ [ "6158TKW0C5" ] ] }, "product_quantity" : "a) 308,275 vials; b) 2,008,850 vials", "state" : "NJ", "recall_initiation_date" : "20120413", "event_id" : "62627", "product_description" : "Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).", "recalling_firm" : "West-ward Pharmaceutical Corp.", "city" : "Eatontown", "@epoch" : 1424553174.836488, "code_info" : "Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13", "reason_for_recall" : "Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.", "distribution_pattern" : "All lots were distributed throughout the US.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20120808", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "02bfc6157b9b7944b8d452b0b66a3fca9e42b3e0ddbfe2b9015c6dbeacbecb30", "initial_firm_notification" : "Letter", "recall_area" : [ "Unknown" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8980" }, "standardHeader" : { "uuid" : "9c039053-7c0f-414b-9755-7473073d2df2", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0324-2015", "openfda" : { "pharm_class_cs" : [ [ "Heparin [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Unfractionated Heparin [EPC]", "Anti-coagulant [EPC]" ] ], "nui" : [ [ "N0000006341", "N0000175474", "N0000175980" ] ], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "NDA018916" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "HEPARIN SODIUM" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "HEPARIN SODIUM" ] ], "rxcui" : [ [ "1362935" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0409-7620-49", "0409-7620-59", "0409-7620-13", "0409-7620-03" ] ], "generic_name" : [ [ "HEPARIN SODIUM" ] ], "spl_id" : [ [ "bdcb13bb-83b4-45f7-9e69-963938f62d11" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0409-7620" ] ], "spl_set_id" : [ [ "32e34077-aff1-4ec7-f9b0-b8e240768fb8" ] ], "unii" : [ [ "T2410KM04A" ] ] }, "product_quantity" : "63,378 flexible container units", "state" : "IL", "recall_initiation_date" : "20140911", "event_id" : "69214", "product_description" : "HEPARIN SODIUM, 1000 USP Heparin Units/500 mL (2 USP Heparin Units/mL), in 0.9% Sodium Chloride Injection, 500 mL flexible container unit, Rx only, Hospira Inc., Lake Forest, IL 60045, NDC 0409-7620-03", "recalling_firm" : "Hospira Inc.", "city" : "Lake Forest", "@epoch" : 1424553174.836488, "code_info" : "Lot #: 41-046-JT, Exp 11/01/2015", "reason_for_recall" : "Presence of Particulate Matter: A particulate, confirmed as human hair, was found sealed between the tube and film at the round seal of the unused administrative port of the container.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20141231", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class I", "@id" : "02f56dda72ba62ca994e8e6c8e3da2e33b284fdb94b8e5f1482dc8db92067e7a", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8981" }, "standardHeader" : { "uuid" : "f454584b-9269-4bfe-b31d-287982c92da6", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-823-2013", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Opioid Agonist [EPC]" ] ], "nui" : [ [ "N0000175690", "N0000175684" ] ], "manufacturer_name" : [ [ "Watson Laboratories, Inc." ] ], "application_number" : [ [ "ANDA040234" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "OXYCODONE AND ACETAMINOPHEN" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "OXYCODONE HYDROCHLORIDE", "ACETAMINOPHEN" ] ], "rxcui" : [ [ "1049658" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0591-0737-01", "0591-0737-05" ] ], "generic_name" : [ [ "OXYCODONE AND ACETAMINOPHEN" ] ], "spl_id" : [ [ "e0af1c2e-6963-4c40-8d57-ce39fa3f36f0" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Full Opioid Agonists [MoA]" ] ], "product_ndc" : [ [ "0591-0737" ] ], "spl_set_id" : [ [ "a1df89be-8dbe-465b-9d52-a4e767ab7dc3" ] ], "unii" : [ [ "CD35PMG570" ] ] }, "product_quantity" : "1,260 bottles", "state" : "CA", "recall_initiation_date" : "20130719", "event_id" : "65747", "product_description" : "Oxycodone and Acetaminophen Capsules, USP 5mg/500 mg, packaged in a)100-count bottle (NDC 0591-0737-01), b) 500-count bottle (NDC 0591-0737-05), Rx only, Manufactured by Watson Laboratories, Inc., Corona, CA92880.", "recalling_firm" : "Watson Laboratories Inc", "city" : "Corona", "@epoch" : 1424553174.836488, "code_info" : "Lot # a) 444971A, Exp 8/13; b) 444973A, Exp 8/13", "reason_for_recall" : "Subpotent drug: Two lots of Oxycodone and Acetaminophen Capsules, USP 5/500 mg are being recalled due to low out of specification (OOS) assay result obtained at expiry (24 months) for the oxycodone portion of the product.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130731", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "0339770dca94dfe33942de00ac9c3d81dbe0189b58c4d1e5e9f442100a14173d", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8982" }, "standardHeader" : { "uuid" : "67d9ace1-d187-48c9-a89e-753a99bf53f8", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1444-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [ [ "67457-218", "67457-219" ] ], "pharm_class_epc" : [ [ "Central alpha-2 Adrenergic Agonist [EPC]" ] ], "nui" : [ [ "N0000009918", "N0000175554" ] ], "manufacturer_name" : [ [ "X-GEN Pharmaceuticals, Inc." ] ], "application_number" : [ [ "ANDA203167" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "CLONIDINE" ] ], "route" : [ [ "EPIDURAL" ] ], "substance_name" : [ [ "CLONIDINE HYDROCHLORIDE" ] ], "rxcui" : [ [ "884225", "884221" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "39822-2000-1", "39822-2010-1" ] ], "generic_name" : [ [ "CLONIDINE" ] ], "spl_id" : [ [ "1f7c533b-a496-4f24-945b-a931f3459a4b" ] ], "upc" : [], "is_original_packager" : [], "pharm_class_moa" : [ [ "Adrenergic alpha2-Agonists [MoA]" ] ], "product_ndc" : [ [ "39822-2000", "39822-2010" ] ], "spl_set_id" : [ [ "ada02f1f-ae78-4435-879e-492ae862d504" ] ], "unii" : [ [ "MN3L5RMN02" ] ] }, "product_quantity" : "8,356 vials", "state" : "NY", "recall_initiation_date" : "20140717", "event_id" : "68729", "product_description" : "Clonidine HCl Injection, 1000 mcg/10 mL (100 mcg/mL),10 mL Single Dose Vial, Rx only, Manufactured for: X-Gen Pharmaceuticals Inc., Big Flats, NY  14814, NDC 39822-2000-1.", "recalling_firm" : "X-Gen Pharmaceuticals Inc.", "city" : "Horseheads", "@epoch" : 1424553174.836488, "code_info" : "Lot: PLNB1412, Exp 12/15", "reason_for_recall" : "Labeling: Label Error On Declared Strength: The side label description incorrectly states \"Each mL contains 500 mcg Clonidine Hydrochloride\" instead of stating \"Each mL contains 100 mcg Clonidine Hydrochloride\".", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140730", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "04cde063c19391eb880fe32326c74cc3cc960f9ae091eb1230ef894382cd29be", "initial_firm_notification" : "E-Mail", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8983" }, "standardHeader" : { "uuid" : "58d710e9-0489-4f21-b5ae-559890b25056", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-687-2013", "openfda" : { "pharm_class_cs" : [ [ "Dihydropyridines [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Dihydropyridine Calcium Channel Blocker [EPC]" ] ], "nui" : [ [ "N0000175421", "N0000007556", "N0000000069" ] ], "manufacturer_name" : [ [ "Caraco Pharmaceutical Laboratories, Ltd." ] ], "application_number" : [ [ "ANDA077067" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "NIMODIPINE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "NIMODIPINE" ] ], "rxcui" : [ [ "198037" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "57664-135-65", "57664-135-64", "57664-135-60" ] ], "generic_name" : [ [ "NIMODIPINE" ] ], "spl_id" : [ [ "b9f244e4-bf34-4f84-9507-4a56e21b8d8e" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Calcium Channel Antagonists [MoA]" ] ], "product_ndc" : [ [ "57664-135" ] ], "spl_set_id" : [ [ "d6a161d9-7e7a-4711-ba0e-c9040c42268d" ] ], "unii" : [ [ "57WA9QZ5WH" ] ] }, "product_quantity" : "46387 Cartons", "state" : "NJ", "recall_initiation_date" : "20130521", "event_id" : "65501", "product_description" : "Nimodipine Capsules 30 mg, Rx Only, For Institutional Use Only, a) 30-count unit dose Capsules (5x6 blister cards per carton), NDC 57664-135-64, b) 100-count unit dose Capsules (25x4 blister cards per carton), NDC 57664-135-65, Distributed by: Caraco Pharmaceutical Laboratories, Ltd. Detroit, MI 48202 Affiliate of Sun Pharmaceutical Industries, Inc.", "recalling_firm" : "Sun Pharmaceutical Industries Inc.", "city" : "Cranbury", "@epoch" : 1424553174.836488, "code_info" : "Lot #s: a) 3305.036B, 3305.037B, Exp Jun-13; 3505.041B, Exp Sep-13; 3305.043B, Exp Nov-13; 3305.044B, Exp Dec-13; 3305.045B  Mar-14.\n\nLot #s: b) 3305.036A, 3305.037A, Exp Jun-13; 3305.038A, Exp Jul-13;  3305.040A,  3505.041A Exp Sep-13; 3305.042A, 3305.043A, Exp Nov-13; 3305.044A  Dec-13.", "reason_for_recall" : "Crystallization; crystallized nimopdipine", "distribution_pattern" : "Nationwide and Puerto Rico", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130717", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "04ec0f51d08b4a3afaed7c804cdbe282139097ba19eb86b28f7e4feb3027867a", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8984" }, "standardHeader" : { "uuid" : "ae35f5f1-2aa3-4a0e-8fba-f50651024c92", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-682-2013", "openfda" : { "pharm_class_cs" : [ [ "Progesterone Congeners [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Progestin [EPC]" ] ], "nui" : [ [ "N0000175602", "N0000011301" ] ], "manufacturer_name" : [ [ "Barr Laboratories Inc." ] ], "application_number" : [ [ "ANDA076380" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "JUNEL 1/20" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "NORETHINDRONE ACETATE", "ETHINYL ESTRADIOL" ] ], "rxcui" : [ [ "1358765", "1359028", "1358763", "1358762", "1359023", "1359022", "259176", "1358780", "1359025", "1359030", "1358776" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0555-9027-42", "0555-9026-58", "0555-9028-58", "0555-9025-42" ] ], "generic_name" : [ [ "NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL" ] ], "spl_id" : [ [ "ceddd4c3-4827-4294-8767-d1e781a1d611" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0555-9025", "0555-9026", "0555-9027", "0555-9028" ] ], "spl_set_id" : [ [ "8b82ad14-580c-4145-b825-dce849f95363" ] ], "unii" : [ [ "T18F433X4S" ] ] }, "product_quantity" : "47,200 blister packs", "state" : "PA", "recall_initiation_date" : "20130315", "event_id" : "64644", "product_description" : "Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58", "recalling_firm" : "Teva Pharmaceuticals USA, Inc.", "city" : "Sellersville", "@epoch" : 1424553174.836488, "code_info" : "NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.", "reason_for_recall" : "Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing", "distribution_pattern" : "Nationwide distribution.  No foreign or government accounts.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130717", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "04ffd7bbbbf26f5dcc9abbc01f965615361a294dd6ca399ae6ab90c926719cbf", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8985" }, "standardHeader" : { "uuid" : "caef923a-b7f6-4c6d-a12e-838688e85523", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0288-2015", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Angiotensin 2 Receptor Blocker [EPC]" ] ], "nui" : [ [ "N0000175561", "N0000000070" ] ], "manufacturer_name" : [ [ "Sandoz Inc" ] ], "application_number" : [ [ "ANDA078702" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "CANDESARTAN CILEXETIL" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "CANDESARTAN CILEXETIL" ] ], "rxcui" : [ [ "577776", "153823", "153822", "639537" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0781-5937-05", "0781-5936-92", "0781-5938-05", "0781-5936-31", "0781-5938-31", "0781-5936-05", "0781-5938-92", "0781-5939-05", "0781-5937-31", "0781-5937-92", "0781-5939-31", "0781-5939-92" ] ], "generic_name" : [ [ "CANDESARTAN CILEXETIL" ] ], "spl_id" : [ [ "d98f02ab-1f3f-40ad-b301-5b5e1f58c140" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Angiotensin 2 Receptor Antagonists [MoA]" ] ], "product_ndc" : [ [ "0781-5939", "0781-5938", "0781-5937", "0781-5936" ] ], "spl_set_id" : [ [ "6498c72c-51cf-4f7d-9a87-2f3c2a3bc95b" ] ], "unii" : [ [ "S8Q36MD2XX" ] ] }, "product_quantity" : "6,336 bottles", "state" : "NJ", "recall_initiation_date" : "20141002", "event_id" : "69688", "product_description" : "candesartan cilexetil, tablets, 16 mg, 90-count bottles, Rx only,  Manufactured for Sandoz Inc., Princeton,  NJ 08540 by Mylan Laboratories Limited Hyderabad, 500 034, India, \nNDC 0781-5938-92", "recalling_firm" : "Sandoz, Inc", "city" : "Princeton", "@epoch" : 1424553174.836488, "code_info" : "Lot #:  3007330, Exp 11/2014", "reason_for_recall" : "Failed Impurities/Degradation Specifications: An Out of Specification (OOS) result was generated for the 18 month stability time point for ketone cilexetil impurity and total impurities.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20141210", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "050f95766010134b69dbbd0b748caa4a9c1e2c38ee89d9e5f0e31609ac6634ce", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8986" }, "standardHeader" : { "uuid" : "03afbbb7-585c-443a-94f2-96b5bd917bf6", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-198-2013", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Corticosteroid [EPC]" ] ], "nui" : [ [ "N0000175576", "N0000175450" ] ], "manufacturer_name" : [ [ "AstraZeneca LP" ] ], "application_number" : [ [ "NDA020929" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "PULMICORT RESPULES" ] ], "route" : [ [ "RESPIRATORY (INHALATION)" ] ], "substance_name" : [ [ "BUDESONIDE" ] ], "rxcui" : [ [ "349094", "351109", "616830", "252559", "616819", "616817" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0186-1990-04", "0186-1988-04", "0186-1989-04" ] ], "generic_name" : [ [ "BUDESONIDE" ] ], "spl_id" : [ [ "37814a0a-646e-44b1-bb71-323bab776259" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Corticosteroid Hormone Receptor Agonists [MoA]" ] ], "product_ndc" : [ [ "0186-1989", "0186-1988", "0186-1990" ] ], "spl_set_id" : [ [ "33cd9834-76df-4f26-3fa2-aab6b9eee8f2" ] ], "unii" : [ [ "J280872D1O" ] ] }, "product_quantity" : "28,476 cartons", "state" : "MA", "recall_initiation_date" : "20130111", "event_id" : "64041", "product_description" : "PULMICORT RESPULES 0.25 mg/2 ml \nBudesonide Inhalation Suspension\n(30 ampules/carton)\nNDC: 0186-1988-04", "recalling_firm" : "AstraZeneca LP", "city" : "Westborough", "@epoch" : 1424553174.836488, "code_info" : "Lot/Exp date:\nAH0054 Exp 5/14; AK0125 Exp 7/14", "reason_for_recall" : "Does Not Meet Monograph: Budesonide may be slightly above or below the specification range.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130320", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "053437757f393c29b838cef16e88b5791e1281761e03061bf4e9311f561fb8d4", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8987" }, "standardHeader" : { "uuid" : "4318a7f9-954e-4497-9d8d-f6c19068121f", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-756-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Histamine-1 Receptor Antagonist [EPC]" ] ], "nui" : [ [ "N0000175587", "N0000000190" ] ], "manufacturer_name" : [ [ "Novartis Consumer Health" ] ], "application_number" : [ [ "part341" ] ], "product_type" : [ [ "HUMAN OTC DRUG" ] ], "brand_name" : [ [ "THERAFLU" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "PHENYLEPHRINE HYDROCHLORIDE", "DIPHENHYDRAMINE HYDROCHLORIDE", "ACETAMINOPHEN" ] ], "rxcui" : [ [ "1489225", "1038851" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0043-6256-06" ] ], "generic_name" : [ [ "ACETAMINOPHEN, DIPHENHYDRAMINE, PHENYLEPHRINE" ] ], "spl_id" : [ [ "f705ff57-2dcb-4a1b-9871-9ab453852570" ] ], "upc" : [ [ "058478105949" ] ], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Histamine H1 Receptor Antagonists [MoA]" ] ], "product_ndc" : [ [ "0043-6256" ] ], "spl_set_id" : [ [ "f705ff57-2dcb-4a1b-9871-9ab453852570" ] ], "unii" : [ [ "8GTS82S83M" ] ] }, "product_quantity" : "3,753,348 cartons", "state" : "NE", "recall_initiation_date" : "20130618", "event_id" : "65490", "product_description" : "Theraflu Nighttime Severe Cold & Cough (acetaminophen 650 mg, diphenhydramine hydrochloride 25 mg, phenylephrine hydrochloride 10 mg) powder packets, Honey Lemon Infused with Chamomille & White Tea flavors, 6-count packets per carton, Distributed by: Novartis Consumer Health, Inc., Parsippany, NJ  07054-0622, NDC 0043-6256-06, UPC 3 0043-6256-06.\n\nAlso packaged under foreign label: NeoCitran Extra Strength Sugar Free Total 7 Symptom Relief (acetaminophen 650 mg, phenylephrine hydrochloride 10 mg, diphenhydramine hydrochloride 25 mg, Soothing Honey Lemon flavor, 10-count single dose pouches per carton, Novartis Consumer Health Canada, Inc., UPC 0 58478 10594 9.", "recalling_firm" : "Novartis Consumer Health", "city" : "Lincoln", "@epoch" : 1424553174.836488, "code_info" : "Lot #: 1011525, 10115834, Exp 5/31/2013; 10116012, 10116043, 10116045, 10116047, 10116049, 10117462, 10118936 Exp 6/30/2013; 10118683, 10118685, 10118934, 10118938, Exp 7/31/2013; 10122278, 10122280, 1012282, Exp 8/31/2013; 10124331, 10124333, 10124335, 10125908, Exp 9/30/2013; 10125923, 10126909, 10126911, 10127023, 10127026, Exp 10/31/2013.\n\nNeoCitran Extra Strength Sugar Free Total 7 Symptom Relief:  10116036, Exp 6/30/2013 and 10122273, Exp 9/30/2013.", "reason_for_recall" : "Presence of Foreign Substance: The products are being recalled because they may contain foreign substances.", "distribution_pattern" : "Nationwide, Mexico, Russia, Korea, Panama, China, and Canada.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140129", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "05f01476ac4554ddc27013aad9e5e19cb7eb9fa603020654b02c37ef44651c57", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8988" }, "standardHeader" : { "uuid" : "c83ecd29-1acb-4021-be38-ed7ccb851d41", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1299-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Atypical Antipsychotic [EPC]" ] ], "nui" : [ [ "N0000175430" ] ], "manufacturer_name" : [ [ "Apotex Corp." ] ], "application_number" : [ [ "ANDA077719" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "RISPERIDONE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "RISPERIDONE" ] ], "rxcui" : [ [ "199387" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "60505-0380-1" ] ], "generic_name" : [ [ "RISPERIDONE" ] ], "spl_id" : [ [ "40648939-c609-2ccd-cb80-b98f47e3364f" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "60505-0380" ] ], "spl_set_id" : [ [ "69d0449f-95ba-dbf6-efde-6b80edee7bad" ] ], "unii" : [ [ "L6UH7ZF8HC" ] ] }, "product_quantity" : "11,422 bottles", "state" : null, "recall_initiation_date" : "20140320", "event_id" : "67985", "product_description" : "Risperidone Oral Solution, 1 mg/mL, 30 mL bottle, Rx only, Manufactured by Apotex Inc., Toronto, Ontario, Canada M9L 1T9, Manufactured for Apotex Corp., Weston, FL 33326, NDC 60505-0380-1.", "recalling_firm" : "Apotex Inc.", "city" : "Toronto", "@epoch" : 1424553174.836488, "code_info" : "Lot #: KD4855, Exp 06/14", "reason_for_recall" : "Failed Impurities/Degradation Specifications: Out of Specification for an impurity at the 18 month stability time point.", "distribution_pattern" : "Nationwide and Puerto Rico.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "CA", "report_date" : "20140507", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "060373c8d11fab4be6940368c83b69e9d26822d8748b938960794ac6737876b8", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f2c60b24f0590ca8989" }, "standardHeader" : { "uuid" : "88f54b68-9609-47b2-b2f7-0b33b8bdfdd8", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1086-2014", "openfda" : { "pharm_class_cs" : [ [ "Calcium [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Phosphate Binder [EPC]", "Calcium [EPC]" ] ], "nui" : [ [ "N0000175597", "N0000020074", "N0000175901", "N0000006512" ] ], "manufacturer_name" : [ [ "Ranbaxy Pharmaceuticals Inc." ] ], "application_number" : [ [ "ANDA076477" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "ATORVASTATIN CALCIUM" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "ATORVASTATIN CALCIUM TRIHYDRATE" ] ], "rxcui" : [], "pharm_class_pe" : [], "package_ndc" : [ [ "63304-830-90", "63304-827-05", "63304-828-05", "63304-827-90", "63304-829-05", "63304-830-05", "63304-828-90", "63304-829-90" ] ], "generic_name" : [ [ "ATORVASTATIN CALCIUM" ] ], "spl_id" : [ [ "66c4e9c7-4bc1-45c1-80ac-6487e6979ff7" ] ], "upc" : [ [ "633048279024" ] ], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Phosphate Chelating Activity [MoA]" ] ], "product_ndc" : [ [ "63304-828", "63304-829", "63304-830", "63304-827" ] ], "spl_set_id" : [ [ "595ab888-6b55-4642-a32f-e8521821ed81" ] ], "unii" : [ [ "SY7Q814VUP" ] ] }, "product_quantity" : "64,626 bottles", "state" : "NJ", "recall_initiation_date" : "20140116", "event_id" : "67485", "product_description" : "Atorvastatin Calcium Tablets, 10 mg, 90-count tablets per bottle, Rx only, Manufactured for: Ranbaxy Pharmaceuticals Inc., Jacksonville, FL 32257 USA; by: Ranbaxy Laboratories Ltd., New Delhi -110 019, India; NDC 63304-827-90", "recalling_firm" : "Ranbaxy Inc.", "city" : "Princeton", "@epoch" : 1424553174.836488, "code_info" : "2407255, 2407256 Exp. 05/14", "reason_for_recall" : "Presence of Foreign Tablets: A product complaint was received by a pharmacist who discovered an Atorvastatin 20 mg tablet inside a sealed bottle of 90-count Atorvastatin 10 mg.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140305", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "062076bb7941223e2a35c3cab53e7f6d342736ff029d6ad16204f99dcb66fa28", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca898a" }, "standardHeader" : { "uuid" : "de2a3a3a-4e0b-4c60-b9d9-65ec308210e0", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1547-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "General Anesthetic [EPC]" ] ], "nui" : [ [ "N0000175681", "N0000175975" ] ], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "ANDA077908" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "PROPOFOL" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "PROPOFOL" ] ], "rxcui" : [ [ "312674" ] ], "pharm_class_pe" : [ [ "General Anesthesia [PE]" ] ], "package_ndc" : [ [ "0409-4699-33", "0409-4699-30", "0409-4699-24" ] ], "generic_name" : [ [ "PROPOFOL" ] ], "spl_id" : [ [ "37d715e6-ef7c-4597-a1d8-0507a3117764" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0409-4699" ] ], "spl_set_id" : [ [ "28d7ba00-f824-4e55-139a-03f509c099db" ] ], "unii" : [ [ "YI7VU623SF" ] ] }, "product_quantity" : "844,300 vials", "state" : "IL", "recall_initiation_date" : "20140402", "event_id" : "67936", "product_description" : "Propofol Injectable Emulsion, 1%, 200 mg/20 mL (10 mg/mL), For I.V. Administration, Rx Only, 20 mL vial, Contains Benzyl Alcohol, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-4699-30", "recalling_firm" : "Hospira Inc.", "city" : "Lake Forest", "@epoch" : 1424553174.836488, "code_info" : "Lot #s: 29-614-DJ, 29-615-DJ, 29-616-DJ, 29-617-DJ, 29-628-DJ, 29-629-DJ, 29-630-DJ, Exp 05/01/2015", "reason_for_recall" : "Presence of Particulate Matter: A glass defect was found on the interior neck of the vial during a retain sample inspection where the glass vial contained visible embedded metallic particulate and free floating metallic particulates were also found in solution.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140827", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class I", "@id" : "0771ad7e43e96e2416146c0971379dc5e632598ef1433b6981b9bb28e84d8ff7", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca898b" }, "standardHeader" : { "uuid" : "b630a1ab-aeb6-49f6-84a1-2a7b5bb8d235", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1615-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [], "nui" : [], "manufacturer_name" : [ [ "Sagent Pharmaceuticals" ] ], "application_number" : [ [ "ANDA202828" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "ZOLEDRONIC ACID" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "ZOLEDRONIC ACID" ] ], "rxcui" : [ [ "705824" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "25021-830-82" ] ], "generic_name" : [ [ "ZOLEDRONIC ACID" ] ], "spl_id" : [ [ "3393610e-f236-429d-8a55-e3d0335576b2" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "25021-830" ] ], "spl_set_id" : [ [ "164500d7-51cf-438a-8bee-7a7dce76ad7a" ] ], "unii" : [] }, "product_quantity" : "10,622 bags", "state" : "IL", "recall_initiation_date" : "20140304", "event_id" : "67689", "product_description" : "Zoledronic Acid Injection 5 mg per 100 mL (0.05 mg/mL), 100 mL single-use bag packaged in a foil overwrap, Rx only, Sterile, For Intravenous Infusion, Mfd. for Sagent Pharmaceuticals Schaumburg, IL ---- NDC 25021-830-82", "recalling_firm" : "Sagent Pharmaceuticals Inc", "city" : "Schaumburg", "@epoch" : 1424553174.836488, "code_info" : "NDC 25021-830-82; Lot Numbers and Expiration Dates: Lot 30076, Expires 01/2015; Lot 30077, Expires 01/2015.", "reason_for_recall" : "Lack of Assurance of Sterility; leaking of premix bags", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20141007", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "07e8b0a404a53aa8a7d6ca00ae4c446edeb89f2a289ed8d738defdbade511287", "initial_firm_notification" : "Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca898c" }, "standardHeader" : { "uuid" : "f5e39c2d-6923-4f12-a4bf-d47765fbb7e9", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0287-2015", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [], "nui" : [], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "NDA018233" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "STERILE WATER" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "WATER" ] ], "rxcui" : [ [ "540930" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0409-7990-09" ] ], "generic_name" : [ [ "WATER" ] ], "spl_id" : [ [ "7e03f338-13de-4b74-ab6e-7b73c8ed7ef5" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0409-7990" ] ], "spl_set_id" : [ [ "107a336c-9195-461b-f897-a920874284b3" ] ], "unii" : [] }, "product_quantity" : "153,504 bags", "state" : "IL", "recall_initiation_date" : "20141014", "event_id" : "69494", "product_description" : "Sterile Water for Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045  NDC 0409-7990-09.", "recalling_firm" : "Hospira Inc.", "city" : "Lake Forest", "@epoch" : 1424553174.836488, "code_info" : "Lot# 36-084-JT; Exp.12/15", "reason_for_recall" : "Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.", "distribution_pattern" : "Nationwide, Puerto Rico, and U.S. Virgin Islands.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20141202", "voluntary_mandated" : null, "classification" : "Class II", "@id" : "07f4bd36ed1e566726c386c0d6450d67b89a79a2b7e0628e84ab90f29f2a067c", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca898d" }, "standardHeader" : { "uuid" : "79f5e205-ac35-401e-97f5-0a7625eee622", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1576-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Serotonin Reuptake Inhibitor [EPC]" ] ], "nui" : [ [ "N0000175696", "N0000000109" ] ], "manufacturer_name" : [ [ "Apotex Corp" ] ], "application_number" : [ [ "NDA020936" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "PAROXETINE HYDROCHLORIDE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "PAROXETINE HYDROCHLORIDE HEMIHYDRATE" ] ], "rxcui" : [ [ "562791", "562790", "562815" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "60505-3674-3", "60505-3675-3", "60505-3673-3" ] ], "generic_name" : [ [ "PAROXETINE HYDROCHLORIDE" ] ], "spl_id" : [ [ "8ef51a3b-8d22-4171-acb2-0294b6a27bc3" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Serotonin Uptake Inhibitors [MoA]" ] ], "product_ndc" : [ [ "60505-3673", "60505-3675", "60505-3674" ] ], "spl_set_id" : [ [ "087ff0d3-1761-47ea-a8c1-7c4cb679af97" ] ], "unii" : [ [ "41VRH5220H" ] ] }, "product_quantity" : null, "state" : null, "recall_initiation_date" : "20140324", "event_id" : "68967", "product_description" : "Paroxetine HCL Controlled-Release Tablets 25 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3674-3", "recalling_firm" : "Apotex Inc.", "city" : "Toronto", "@epoch" : 1424553174.836488, "code_info" : "Lot # 2A002, Exp. 01/15\nLot # 2A003, Exp. 01/15\nLot # 2C004, Exp. 03/15\nLot # 2C005, Exp. 03/15\nLot # 2E008, Exp. 05/15\nLot # 2F009, Exp. 06/15\nLot # 2F010, Exp. 06/15\nLot # 2H011, Exp. 08/15\nLot # 2H012, Exp. 08/15\nLot # 2H013, Exp. 0815", "reason_for_recall" : "Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.", "distribution_pattern" : "Nationwide and Puerto Rico", "status" : "Ongoing", "product_type" : "Drugs", "country" : "CA", "report_date" : "20140910", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "081cfb585f9d424f8992982999ae238e2aabe66bc3faa651ec3771e6c062ebe2", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca898e" }, "standardHeader" : { "uuid" : "45f1a95b-cf83-4b66-b583-4dab1a6cc76a", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0286-2015", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [], "nui" : [], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "NDA018090" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "SODIUM CHLORIDE" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "SODIUM CHLORIDE" ] ], "rxcui" : [ [ "313002", "237372" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0409-7983-61", "0409-7983-09", "0409-7984-20", "0409-7983-02", "0409-7983-03", "0409-7984-23", "0409-7985-02", "0409-7985-03", "0409-7730-20", "0409-7984-36", "0409-7984-13", "0409-7730-37", "0409-7730-36", "0409-7984-37", "0409-7983-53", "0409-7983-55", "0409-7985-09" ] ], "generic_name" : [ [ "SODIUM CHLORIDE" ] ], "spl_id" : [ [ "75f46495-4f3f-4a64-99c6-c6febd48ba79" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0409-7983", "0409-7730", "0409-7985", "0409-7984" ] ], "spl_set_id" : [ [ "089fc1de-00ae-41b6-7c97-1217f0cecc03" ] ], "unii" : [] }, "product_quantity" : "784,920 bags", "state" : "IL", "recall_initiation_date" : "20141014", "event_id" : "69494", "product_description" : "0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7985-09.", "recalling_firm" : "Hospira Inc.", "city" : "Lake Forest", "@epoch" : 1424553174.836488, "code_info" : "Lot # 33-027-JT; Exp.09/15\nLot # 33-045-JT; Exp.09/15\nLot # 33-097-JT; Exp.09/15\nLot # 35-068-JT; Exp.11/15\nLot # 36-112-JT; Exp.12/15\nLot # 37-012-JT; Exp.01/15", "reason_for_recall" : "Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.", "distribution_pattern" : "Nationwide, Puerto Rico, and U.S. Virgin Islands.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20141202", "voluntary_mandated" : null, "classification" : "Class II", "@id" : "0915f2e5d95bda16d4f20e3e8808b9c7a5233fb7e3e15cfbb4e5f2b17b34d86c", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca898f" }, "standardHeader" : { "uuid" : "eda6a577-3dd0-47e0-822a-69798e4af258", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1438-2012", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Anti-epileptic Agent [EPC]" ] ], "nui" : [ [ "N0000175753", "N0000008486" ] ], "manufacturer_name" : [ [ "West-ward Pharmaceutical Corp" ] ], "application_number" : [ [ "ANDA078765" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "FOSPHENYTOIN SODIUM" ] ], "route" : [ [ "INTRAMUSCULAR", "INTRAVENOUS" ] ], "substance_name" : [ [ "FOSPHENYTOIN SODIUM" ] ], "rxcui" : [ [ "855893" ] ], "pharm_class_pe" : [ [ "Decreased Central Nervous System Disorganized Electrical Activity [PE]" ] ], "package_ndc" : [ [ "0143-9788-25", "0143-9782-10", "0143-9703-10" ] ], "generic_name" : [ [ "FOSPHENYTOIN SODIUM" ] ], "spl_id" : [ [ "4306f506-de2f-42e7-a0b6-5a1eb1d481c2" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0143-9782", "0143-9788" ] ], "spl_set_id" : [ [ "c92df63b-5140-4213-8d43-8327ff6230b7" ] ], "unii" : [ [ "6158TKW0C5" ] ] }, "product_quantity" : "a) 74,960 vials; b) 911,070 vials", "state" : "NJ", "recall_initiation_date" : "20120413", "event_id" : "62627", "product_description" : "Fosphenytoin Sodium Injection, USP, 500 mg PE per 10 mL (50 mg PE per mL), 10 mL Single Dose Vial, packaged in 10-count x 10 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9703-10), b) West-Ward (NDC 0143-9782-10).", "recalling_firm" : "West-ward Pharmaceutical Corp.", "city" : "Eatontown", "@epoch" : 1424553174.836488, "code_info" : "Lot #s: a) 112161.1, 112162.1, 112163.1, Exp 05/13; b) 102165.2, 102167.1, Exp 05/12; 102190.1, 102191.1, 102191.2, 102192.1, 102213.1, Exp 07/12; 102240.1, 102241.1, 10227.1, 102272.1, 102272.2, 102273.1, 102274.1, 102275.1, Exp 09/12; 102319.1, 102320.1, 102321.1, 102322.1, 102323.1, 102324.1, 102325.1, Exp 11/12; 102342.1, 102343.1, 102344.1, 102345.1, Exp 12/12; 112019.1, 112020.1, 112021.1, 112022.1, 112023.1, Exp 01/13; 112156.1, 112157.1, 112158.1, 112159.1, 112160.1, Exp 05/13; 112164.1, Exp 06/13; 112203.1, 112204.1, 112205.1, 112206.1, Exp 07/13; 112262.1, 112263.1, Exp 09/13; 112301.1, 112302.1, 112303.1, 112304.1, Exp 10/13; 112323.1, 112324.1, 112325.1, Exp 11/13", "reason_for_recall" : "Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.", "distribution_pattern" : "All lots were distributed throughout the US.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20120808", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "0954571496d32f461ac5444b8b927ecbbfd0156dba426095289e9ddfae6c7249", "initial_firm_notification" : "Letter", "recall_area" : [ "Unknown" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca8990" }, "standardHeader" : { "uuid" : "6323384a-741c-414f-acda-9b532ad35fda", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1662-2012", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Antirheumatic Agent [EPC]" ] ], "nui" : [ [ "N0000175713" ] ], "manufacturer_name" : [ [ "Apotex Corp." ] ], "application_number" : [ [ "ANDA077090" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "LEFLUNOMIDE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "LEFLUNOMIDE" ] ], "rxcui" : [ [ "205285", "205284" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "60505-2503-1", "60505-2503-2", "60505-2503-3", "60505-2502-1", "60505-2502-3", "60505-2502-2" ] ], "generic_name" : [ [ "LEFLUNOMIDE" ] ], "spl_id" : [ [ "fe1ea007-6d6e-1d29-5bd0-6ac7174b6136" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "60505-2502", "60505-2503" ] ], "spl_set_id" : [ [ "753453c5-8a7a-878e-3ce7-1d1edce718a9" ] ], "unii" : [ [ "G162GK9U4W" ] ] }, "product_quantity" : "31", "state" : "FL", "recall_initiation_date" : "20070614", "event_id" : "38329", "product_description" : "Leflunomide tablets, 20 mg, 1000-count bottle, Rx only, Manufactured for Apotex Corp., Weston, Florida 33326 by Apotex Inc., Toronto, Ontario Canada M9L 1T9, NDC 60505-2503-3", "recalling_firm" : "Apotex Corp.", "city" : "Weston", "@epoch" : 1424553174.836488, "code_info" : "Lot #: GZ1274, Exp 11/07.", "reason_for_recall" : "Subpotent (Single Ingredient Drug): Distribution of product that did not meet specifications.", "distribution_pattern" : "Nationwide.", "status" : "Terminated", "product_type" : "Drugs", "country" : "US", "report_date" : "20120905", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "098096b7dfc18ee604abf55468cbdf505d63e72d7fa07bcaff114152ae5a4724", "initial_firm_notification" : "FAX", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca8991" }, "standardHeader" : { "uuid" : "0042fcce-7beb-404e-8727-8c5cc7daeeda", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1234-2014", "openfda" : { "pharm_class_cs" : [ [ "Amides [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Amide Local Anesthetic [EPC]", "Antiarrhythmic [EPC]" ] ], "nui" : [ [ "N0000175682", "N0000007681", "N0000175976", "N0000175426" ] ], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "ANDA080408" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "LIDOCAINE HYDROCHLORIDE" ] ], "route" : [ [ "EPIDURAL", "INFILTRATION" ] ], "substance_name" : [ [ "LIDOCAINE HYDROCHLORIDE" ] ], "rxcui" : [ [ "1010671", "1010033", "1010618", "1010900" ] ], "pharm_class_pe" : [ [ "Local Anesthesia [PE]" ] ], "package_ndc" : [ [ "0409-4713-65", "0409-4713-62", "0409-4056-01", "0409-4282-02", "0409-4270-01", "0409-4276-01", "0409-4276-02", "0409-4277-02", "0409-4277-01", "0409-4278-01", "0409-4713-02", "0409-4713-01", "0409-4713-32", "0409-4282-01", "0409-4279-02", "0409-4275-01", "0409-4776-01" ] ], "generic_name" : [ [ "LIDOCAINE HYDROCHLORIDE" ] ], "spl_id" : [ [ "0cc59b8b-e04d-40ec-9597-afb5f650f889" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0409-4270", "0409-4056", "0409-4713", "0409-4275", "0409-4276", "0409-4277", "0409-4278", "0409-4279", "0409-4282", "0409-4776" ] ], "spl_set_id" : [ [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ] ], "unii" : [ [ "98PI200987" ] ] }, "product_quantity" : "374,500 vials", "state" : "IL", "recall_initiation_date" : "20130916", "event_id" : "66441", "product_description" : "1% Lidocaine HCl Injection, USP, 10 mg/mL, NDC 0409-4276-01, Hospira, Inc., Lake Forest, IL 60045.", "recalling_firm" : "Hospira, Inc.", "city" : "Lake Forest", "@epoch" : 1424553174.836488, "code_info" : "Lot #25090DK; Exp 01/15", "reason_for_recall" : "Presence of Particulate Matter: Oxidized stainless steel found in vial of 1% Lidocaine Hydrochloride Injection, USP.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140423", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class I", "@id" : "09aa803882266d04fb64a4265eb319726d9630f8663e4c346b3ee941058ff032", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca8992" }, "standardHeader" : { "uuid" : "df37af03-0a87-40cd-9434-fa2c5078b107", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0338-2015", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Anti-epileptic Agent [EPC]" ] ], "nui" : [ [ "N0000175753", "N0000008486" ] ], "manufacturer_name" : [ [ "Actavis Inc." ] ], "application_number" : [ [ "ANDA075350" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "GABAPENTIN" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "GABAPENTIN" ] ], "rxcui" : [ [ "310432", "310431", "310430" ] ], "pharm_class_pe" : [ [ "Decreased Central Nervous System Disorganized Electrical Activity [PE]" ] ], "package_ndc" : [ [ "45963-555-50", "45963-555-11", "45963-557-11", "45963-556-11", "45963-556-50", "45963-557-50" ] ], "generic_name" : [ [ "GABAPENTIN" ] ], "spl_id" : [ [ "e3189f16-0d74-4422-89a6-9427d71130fd" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "45963-557", "45963-556", "45963-555" ] ], "spl_set_id" : [ [ "5969871e-6c71-4c37-9d63-370718ccc80c" ] ], "unii" : [ [ "6CW7F3G59X" ] ] }, "product_quantity" : "29,622 Bottles", "state" : "NJ", "recall_initiation_date" : "20141215", "event_id" : "70001", "product_description" : "Gabapentin Capsules, USP, 100 mg, Rx Only, a) 100 capsules per bottle, NDC 45963-555-11, b) 500 Capsules per bottle, NDC 45963-555-50, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA.", "recalling_firm" : "Actavis Elizabeth LLC", "city" : "Elizabeth", "@epoch" : 1424553174.836488, "code_info" : "Lot #s: a) G01966A1, Exp 10/2015, b) G02004A1, Exp 03/2016", "reason_for_recall" : "Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.", "distribution_pattern" : "Puerto Rico", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20150114", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "09d96fc580f2da8ddb40ea7bbcd750353de383c229e488f4d20aa6e5690e6b07", "initial_firm_notification" : "Letter", "recall_area" : [ "Puerto Rico" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca8993" }, "standardHeader" : { "uuid" : "3280e9a5-dc0c-4efb-808f-8d357e7c0c77", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0422-2015", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Typical Antipsychotic [EPC]" ] ], "nui" : [ [ "N0000180182" ] ], "manufacturer_name" : [ [ "Mylan Institutional LLC" ] ], "application_number" : [ [ "ANDA075440" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "HALOPERIDOL DECANOATE" ] ], "route" : [ [ "INTRAMUSCULAR" ] ], "substance_name" : [ [ "HALOPERIDOL DECANOATE" ] ], "rxcui" : [ [ "859867", "859871" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "67457-381-58", "67457-382-58", "67457-410-13", "67457-409-13", "67457-410-00", "67457-409-00", "67457-381-00", "67457-382-00" ] ], "generic_name" : [ [ "HALOPERIDOL DECANOATE" ] ], "spl_id" : [ [ "5cb2c072-8782-4f5b-834f-6fe97991598c" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "67457-409", "67457-410", "67457-382", "67457-381" ] ], "spl_set_id" : [ [ "8ffac6fb-1702-40d6-b085-152d24673cbd" ] ], "unii" : [ [ "J6292F8L3D" ] ] }, "product_quantity" : "2,523 cartons (25,936 vials)", "state" : "IL", "recall_initiation_date" : "20150218", "event_id" : "70564", "product_description" : "Haloperidol Decanoate Injection, 50 mg/mL, For Intra Muscular Use Only, 1 mL single dose vials (NDC 67457-410-00) packaged in cartons of ten (NDC 67457-410-13), Rx only, Manufactured in India for: Mylan Institutional LLC Rockford, IL 61103", "recalling_firm" : "Mylan Institutional LLC", "city" : "Rockford", "@epoch" : 1428088411.295797, "code_info" : "Lot 7602368, Exp 7/16; Lot 7602369, Exp 7/16", "reason_for_recall" : "Lack of Assurance of Sterility; due to leaking vials", "distribution_pattern" : "Nationwide and Puerto Rico", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20150401", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "0b048f391548465520addf1bddcc9777a688e26495b88aed7b5373f78b50920a", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca8994" }, "standardHeader" : { "uuid" : "1295a314-4390-4ba3-8710-25b47f722965", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1067-2013", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Serotonin and Norepinephrine Reuptake Inhibitor [EPC]" ] ], "nui" : [ [ "N0000175749", "N0000000109", "N0000000102" ] ], "manufacturer_name" : [ [ "Kremers Urban Pharmaceuticals Inc." ] ], "application_number" : [ [ "NDA022104" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "VENLAFAXINE HYDROCHLORIDE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "VENLAFAXINE HYDROCHLORIDE" ] ], "rxcui" : [ [ "808744", "808753", "808748", "808751" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0131-3266-46", "0131-3267-32", "0131-3267-46", "0131-3265-46", "0131-3268-46", "0131-3268-32", "0131-3265-32", "0131-3266-32" ] ], "generic_name" : [ [ "VENLAFAXINE HYDROCHLORIDE" ] ], "spl_id" : [ [ "46596bfd-f89e-46c4-9ff8-e5e19917fb69" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Norepinephrine Uptake Inhibitors [MoA]", "Serotonin Uptake Inhibitors [MoA]" ] ], "product_ndc" : [ [ "0131-3266", "0131-3267", "0131-3265", "0131-3268" ] ], "spl_set_id" : [ [ "908bc748-21e3-4f07-bab3-8e3b3da99be0" ] ], "unii" : [ [ "GRZ5RCB1QG" ] ] }, "product_quantity" : "57857 bottles", "state" : "GA", "recall_initiation_date" : "20130916", "event_id" : "66226", "product_description" : "Venlafaxine (Venlafaxine Hydrochloride) extended release Tablets, 225 mg, packaged in a) 30- count bottle (NDC 0131-3268-32) and b) 90-count bottle (NDC: 0131-3268-46), Rx only, Manufactured by: Kremers Urban Pharmaceuticals Inc. For: Osmotica Pharmaceutical Corp., Wilmington, NC 28405, USA.", "recalling_firm" : "Osmotica Pharmaceutical Corp", "city" : "Marietta", "@epoch" : 1424553174.836488, "code_info" : "Lot #: a) 58975, 58976, 58977, 65165 , Exp 01/14; b) 58973, 58974, 65131, Exp: 01/14", "reason_for_recall" : "Failed Dissolution Specification; 12 hour time point at 18 months shelf life", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20131009", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "0b5b9c7194d10259a9fd7ebdd3cdf68c9636a7e2d663ea8bc0a1c6b50aa85a9b", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca8995" }, "standardHeader" : { "uuid" : "3c2449ae-6907-4889-af6f-90c266867317", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0389-2015", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "General Anesthetic [EPC]" ] ], "nui" : [ [ "N0000175681", "N0000175975" ] ], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "ANDA077908" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "PROPOFOL" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "PROPOFOL" ] ], "rxcui" : [ [ "312674" ] ], "pharm_class_pe" : [ [ "General Anesthesia [PE]" ] ], "package_ndc" : [ [ "0409-4699-33", "0409-4699-30", "0409-4699-24" ] ], "generic_name" : [ [ "PROPOFOL" ] ], "spl_id" : [ [ "cf803931-7b18-480a-a86a-7cc9c065890b" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0409-4699" ] ], "spl_set_id" : [ [ "28d7ba00-f824-4e55-139a-03f509c099db" ] ], "unii" : [ [ "YI7VU623SF" ] ] }, "product_quantity" : "2,500 vials", "state" : "IL", "recall_initiation_date" : "20141006", "event_id" : "69573", "product_description" : "Propofol Injectable Emulsion, 1%, 200 mg/20 mL (10 mg/mL), 20 mL Single patient infusion vials, packaged in 5 Units per carton, Rx only, Hospira, Inc., Lake Forest, IL  60045, NDC 0409-4699-30.", "recalling_firm" : "Hospira Inc.", "city" : "Lake Forest", "@epoch" : 1428088411.295797, "code_info" : "One shipment of Lot #: 33-750-DJ; Exp 1SEP2015 to The Harvard Drug Group, Livonia, MI", "reason_for_recall" : "Temperature Abuse: Products experienced uncontrolled temperature excursions during transit.", "distribution_pattern" : "Distribution limited to one shipment to The Harvard Drug Group, Livonia, MI for the lots of Vancomycin 500 mg, Ketorolac tromethamine 60 mg/2 mL (30 mg/mL), and Propofol 1% 200 mg/20 mL (10 mg/mL), these lots remained within the control of the distributor and were not further distributed. Distribution was Nationwide for the Vancomycin 1 g product.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20150225", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class I", "@id" : "0c257f826c5c880a6b8252940bb8bf9eabf165b46e36bcbdcb75e783aea6c5b8", "initial_firm_notification" : "Telephone", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca8996" }, "standardHeader" : { "uuid" : "7e5a7f03-99ee-49fe-b1c1-0db91e2181f9", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0388-2015", "openfda" : { "pharm_class_cs" : [ [ "Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Nonsteroidal Anti-inflammatory Drug [EPC]" ] ], "nui" : [ [ "N0000000160", "N0000175722", "N0000175721" ] ], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "ANDA074802" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "KETOROLAC TROMETHAMINE" ] ], "route" : [ [ "INTRAMUSCULAR", "INTRAVENOUS" ] ], "substance_name" : [ [ "KETOROLAC TROMETHAMINE" ] ], "rxcui" : [ [ "860096", "860092" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0409-3793-01", "0409-3795-01", "0409-3796-01" ] ], "generic_name" : [ [ "KETOROLAC TROMETHAMINE" ] ], "spl_id" : [ [ "0c5de268-3945-429c-9c3b-69dfb19344c1" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Cyclooxygenase Inhibitors [MoA]" ] ], "product_ndc" : [ [ "0409-3793", "0409-3796", "0409-3795" ] ], "spl_set_id" : [ [ "8accbb78-fc64-45d5-69b0-35c23a1d2a2e" ] ], "unii" : [ [ "YZI5105V0L" ] ] }, "product_quantity" : "100 vials", "state" : "IL", "recall_initiation_date" : "20141006", "event_id" : "69573", "product_description" : "Ketorolac Tromethamine Inj., USP, 60 mg (30 mg/mL), 2 mL Single-dose Fliptop Vial, packaged in 25 Units per carton, Rx only, Hospira, Inc., Lake Forest, IL  60045, NDC 0409-3796-01.", "recalling_firm" : "Hospira Inc.", "city" : "Lake Forest", "@epoch" : 1428088411.295797, "code_info" : "One shipment of Lot #: 34-540-DK; Exp 1OCT2015 to The Harvard Drug Group, Livonia, MI", "reason_for_recall" : "Temperature Abuse: Products experienced uncontrolled temperature excursions during transit.", "distribution_pattern" : "Distribution limited to one shipment to The Harvard Drug Group, Livonia, MI for the lots of Vancomycin 500 mg, Ketorolac tromethamine 60 mg/2 mL (30 mg/mL), and Propofol 1% 200 mg/20 mL (10 mg/mL), these lots remained within the control of the distributor and were not further distributed. Distribution was Nationwide for the Vancomycin 1 g product.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20150225", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "0c59869e33111d02b4d84c15f3c26849de7321aa11125f5a967a5d450e235e89", "initial_firm_notification" : "Telephone", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca8997" }, "standardHeader" : { "uuid" : "9ede1d17-f471-404d-9746-70130458fad1", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1539-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Cholinergic Muscarinic Antagonist [EPC]" ] ], "nui" : [ [ "N0000175700", "N0000000125" ] ], "manufacturer_name" : [ [ "Mylan Pharmaceuticals Inc." ] ], "application_number" : [ [ "ANDA202641" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "TOLTERODINE TARTRATE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "TOLTERODINE TARTRATE" ] ], "rxcui" : [ [ "855178", "855194" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0378-5446-69", "0378-5446-91", "0378-5445-05", "0378-5445-69", "0378-5445-91", "0378-5446-05" ] ], "generic_name" : [ [ "TOLTERODINE" ] ], "spl_id" : [ [ "bfc370b4-6a62-44de-a353-dd59768e3133" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Cholinergic Muscarinic Antagonists [MoA]" ] ], "product_ndc" : [ [ "0378-5445", "0378-5446" ] ], "spl_set_id" : [ [ "304023e8-57ad-4dd7-9cf0-a4524623aa6c" ] ], "unii" : [ [ "WHE7A56U7K" ] ] }, "product_quantity" : "9225 Bottles", "state" : "WV", "recall_initiation_date" : "20140620", "event_id" : "68642", "product_description" : "Tolterodine Tartrate Tablets, 1 mg, 60 Tablet Bottles, Rx only.  Mylan Pharmaceuticals Inc., Morgantown, WV 26505. NDC: 0378-5445-91.", "recalling_firm" : "Mylan Pharmaceuticals Inc.", "city" : "Morgantown", "@epoch" : 1424553174.836488, "code_info" : "Lot # 2004069, Expiry: 09/2014; Lot #: 2004070, Expiry: 09/2014.", "reason_for_recall" : "Failed Impurities/Degradation Specifications; Out of specification for lactol and total impurities.", "distribution_pattern" : "U.S. Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140827", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "0c6d9bcc76d798581fc7fcd670b2cb46365c8002c321be66755cf982c1fc7831", "initial_firm_notification" : "E-Mail", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca8998" }, "standardHeader" : { "uuid" : "83596e46-7126-4af6-aa26-fdad28adb048", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-836-2013", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [], "nui" : [], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "NDA018090" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "SODIUM CHLORIDE" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "SODIUM CHLORIDE" ] ], "rxcui" : [ [ "313002", "237372" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0409-7983-61", "0409-7983-09", "0409-7984-20", "0409-7983-02", "0409-7983-03", "0409-7984-23", "0409-7985-02", "0409-7985-03", "0409-7730-20", "0409-7984-36", "0409-7984-13", "0409-7730-37", "0409-7730-36", "0409-7984-37", "0409-7983-53", "0409-7983-55", "0409-7985-09" ] ], "generic_name" : [ [ "SODIUM CHLORIDE" ] ], "spl_id" : [ [ "75f46495-4f3f-4a64-99c6-c6febd48ba79" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0409-7983", "0409-7730", "0409-7985", "0409-7984" ] ], "spl_set_id" : [ [ "089fc1de-00ae-41b6-7c97-1217f0cecc03" ] ], "unii" : [] }, "product_quantity" : "691,356 containers", "state" : "IL", "recall_initiation_date" : "20130329", "event_id" : "64792", "product_description" : "0.9% Sodium Chloride Injection, USP, 1000 mL flexible container, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7983-09.", "recalling_firm" : "Hospira Inc.", "city" : "Lake Forest", "@epoch" : 1424553174.836488, "code_info" : "Lot #: 25-037-JT*, Exp 1JAN2015, Note: the lot number may be followed by 01 or 90", "reason_for_recall" : "Presence of Particulate Matter: reports of small grey/brown particles found in the primary container identified as brass particulates", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130814", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class I", "@id" : "0cf6cb0a7260b7e565a3b852e984a51d7d7ed6aa2c1f69547f365b33c6b41b3d", "initial_firm_notification" : "Press Release", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca8999" }, "standardHeader" : { "uuid" : "0a32113f-3059-4aed-9753-5c2e8cfce4b2", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1610-2014", "openfda" : { "pharm_class_cs" : [ [ "Calcium [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Phosphate Binder [EPC]", "Calcium [EPC]" ] ], "nui" : [ [ "N0000175597", "N0000020074", "N0000175901", "N0000006512" ] ], "manufacturer_name" : [ [ "Baxter Healthcare Corporation" ] ], "application_number" : [ [ "NDA017512" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "DIANEAL LOW CALCIUM WITH DEXTROSE" ] ], "route" : [ [ "INTRAPERITONEAL" ] ], "substance_name" : [ [ "SODIUM CHLORIDE", "CALCIUM CHLORIDE", "SODIUM LACTATE", "MAGNESIUM CHLORIDE", "DEXTROSE MONOHYDRATE" ] ], "rxcui" : [ [ "800472", "800057", "800064", "800066", "800061", "800062", "800074", "799999", "800111", "800474", "800003", "800115" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0941-0415-40", "0941-0415-41", "0941-0415-42", "0941-0415-43", "0941-0415-44", "0941-0415-45", "0941-0457-48", "0941-0415-47", "0941-0415-48", "0941-0457-47", "0941-0459-28", "0941-0457-45", "0941-0424-55", "0941-0424-53", "0941-0424-52", "0941-0424-51", "0941-0409-05", "0941-0409-07", "0941-0409-06", "0941-0409-01", "0941-0457-49", "0941-0409-08", "0941-0433-53", "0941-0415-49", "0941-0433-52", "0941-0433-51", "0941-0411-48", "0941-0426-51", "0941-0426-53", "0941-0426-52", "0941-0413-28", "0941-0411-49", "0941-0411-45", "0941-0411-46", "0941-0411-40", "0941-0411-41", "0941-0411-42", "0941-0411-43", "0941-0413-25", "0941-0457-28", "0941-0457-25", "0941-0430-55", "0941-0430-52", "0941-0430-53", "0941-0430-51", "0941-0426-55", "0941-0413-08", "0941-0413-01", "0941-0413-06", "0941-0413-07", "0941-0413-04", "0941-0413-05", "0941-0459-48", "0941-0459-49", "0941-0459-45", "0941-0459-47", "0941-0415-08", "0941-0411-28", "0941-0415-04", "0941-0415-05", "0941-0415-06", "0941-0415-07", "0941-0415-01", "0941-0433-55", "0941-0409-49", "0941-0409-48", "0941-0457-08", "0941-0457-02", "0941-0457-01", "0941-0409-45", "0941-0457-07", "0941-0457-05", "0941-0411-25", "0941-0459-25", "0941-0411-04", "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-08", "0941-0409-36", "0941-0429-55", "0941-0429-51", "0941-0429-52", "0941-0429-53", "0941-0459-05", "0941-0415-28", "0941-0459-07", "0941-0459-01", "0941-0459-02", "0941-0459-08", "0941-0415-25", "0941-0411-11", "0941-0409-28", "0941-0409-27", "0941-0427-52", "0941-0427-53", "0941-0427-51", "0941-0427-55", "0941-0413-48", "0941-0413-49", "0941-0413-47", "0941-0413-44", "0941-0413-45", "0941-0413-42", "0941-0413-43", "0941-0413-40", "0941-0413-41" ] ], "generic_name" : [ [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ] ], "spl_id" : [ [ "3cbff926-5ff1-42a5-b5a9-f711fbb57ef9" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Phosphate Chelating Activity [MoA]" ] ], "product_ndc" : [ [ "0941-0413", "0941-0411", "0941-0415", "0941-0429", "0941-0426", "0941-0427", "0941-0424", "0941-0409", "0941-0433", "0941-0430", "0941-0457", "0941-0459" ] ], "spl_set_id" : [ [ "aa268d3f-7389-4f25-801f-5d4825495f08" ] ], "unii" : [ [ "SY7Q814VUP" ] ] }, "product_quantity" : "50,530 bags", "state" : "IL", "recall_initiation_date" : "20140807", "event_id" : "69011", "product_description" : "Dianeal Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose, 5000 mL Ambu-Flex II container bags, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015; Product Code L5B5202, NDC 0941-0457-05.", "recalling_firm" : "Baxter Healthcare Corp.", "city" : "Deerfield", "@epoch" : 1424553174.836488, "code_info" : "Lot #: C940700, C940841, Exp 05/16", "reason_for_recall" : "Presence of Particulate Matter: particulate matter was found during the manufacturing process.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20141007", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class I", "@id" : "0d803df5f427878aae1f5884f725135d3dd89351604869097515664fb7c8a1c5", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca899a" }, "standardHeader" : { "uuid" : "a9351586-02a4-4c1e-a217-30348778b684", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-001-2013", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [ [ "67767-142", "67767-141" ] ], "pharm_class_epc" : [ [ "Aminoketone [EPC]" ] ], "nui" : [ [ "N0000009282", "N0000000114", "N0000180855", "N0000009456", "N0000000102" ] ], "manufacturer_name" : [ [ "McKesson Packaging Services a Business unit of McKesson Corporation" ] ], "application_number" : [ [ "ANDA077285" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "BUPROPION HYDROCHLORIDE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "BUPROPION HYDROCHLORIDE" ] ], "rxcui" : [ [ "993557", "993541" ] ], "pharm_class_pe" : [ [ "Increased Norepinephrine Activity [PE]", "Increased Dopamine Activity [PE]" ] ], "package_ndc" : [ [ "63739-449-10", "63739-450-10", "6373944910" ] ], "generic_name" : [ [ "BUPROPION HYDROCHLORIDE" ] ], "spl_id" : [ [ "8ad0c59a-8772-4c94-809a-aaccecadab60" ] ], "upc" : [], "is_original_packager" : [], "pharm_class_moa" : [ [ "Norepinephrine Uptake Inhibitors [MoA]", "Dopamine Uptake Inhibitors [MoA]" ] ], "product_ndc" : [ [ "63739-450", "63739-449" ] ], "spl_set_id" : [ [ "64d4bbee-1cc4-409e-b65a-1f2e927cf0d1" ] ], "unii" : [ [ "01ZG3TPX31" ] ] }, "product_quantity" : "187 cartons", "state" : "NC", "recall_initiation_date" : "20120329", "event_id" : "63127", "product_description" : "buPROPion Hydrochloride Extended-Release Tablets (XL), 150 mg, UD 100 Tablets (10 x 10) per carton, Rx only, Mfg By: CMIC-VPS Corporation, Cranbury, New Jersey  08512; blister barcode N (01)003 63739 449 10 7, Dist By: McKesson Packaging, Concord, NC  28027; NDC 63739-449-10, carton barcode 6373944910.", "recalling_firm" : "McKesson Packaging Services", "city" : "Concord", "@epoch" : 1424553174.836488, "code_info" : "Lot #: 0074583, Exp. Date 03/12", "reason_for_recall" : "Failed USP Dissolution Test Requirements: Possible out-of-specification dissolution results at the 8 hour stability testing point.", "distribution_pattern" : "Nationwide", "status" : "Completed", "product_type" : "Drugs", "country" : "US", "report_date" : "20121010", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "0daf85e9da209660c5af90c1425457850394dc3d17e76f2395f0695ec4a74b69", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca899b" }, "standardHeader" : { "uuid" : "1f215206-9443-46a9-838e-a6e1955e9292", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-132-2013", "openfda" : { "pharm_class_cs" : [ [ "Thiazides [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Thiazide Diuretic [EPC]" ] ], "nui" : [ [ "N0000166469", "N0000175419", "N0000175359" ] ], "manufacturer_name" : [ [ "West-Ward Pharmaceutical Corp" ] ], "application_number" : [ [ "ANDA076265" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "LISINOPRIL WITH HYDROCHLOROTHIAZIDE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "HYDROCHLOROTHIAZIDE", "LISINOPRIL" ] ], "rxcui" : [ [ "197885", "197887", "197886" ] ], "pharm_class_pe" : [ [ "Increased Diuresis [PE]" ] ], "package_ndc" : [ [ "0143-1262-10", "0143-1264-01", "0143-1262-01", "0143-1264-05", "0143-1264-10", "0143-1262-05", "0143-1264-30", "0143-1263-30", "0143-1263-05", "0143-1263-01", "0143-1262-30", "0143-1263-10" ] ], "generic_name" : [ [ "LISINOPRIL AND HYDROCHLOROTHIAZIDE" ] ], "spl_id" : [ [ "a0b8198a-a2b4-40ea-bddd-a3f5c8462852" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0143-1264", "0143-1263", "0143-1262" ] ], "spl_set_id" : [ [ "6573671e-3386-43d0-8f7c-bb8456bdfcbd" ] ], "unii" : [ [ "0J48LPH2TH" ] ] }, "product_quantity" : "43,478 bottles", "state" : "NJ", "recall_initiation_date" : "20121130", "event_id" : "63967", "product_description" : "Lisinopril and Hydrochlorothiazide Tablets, 20 mg/25 mg, packaged in a) 100-count tablets per bottle (NDC 0143-1264-01) and b) 1000-count tablets per bottle (NDC 0143-1264-10), Rx only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724.", "recalling_firm" : "West-ward Pharmaceutical Corp.", "city" : "Eatontown", "@epoch" : 1424553174.836488, "code_info" : "Lot #: 69392A,  69393A, 69394A, 69395A, 69396A, 69397A , Exp 09/15; 69495A, 69496A, 69497A, 69498A, 69524A, 69525A, Exp 10/15", "reason_for_recall" : "Presence of Foreign Substance: Reports of gray smudges identified as minute stainless steel particulates were found in the recalled tablets.", "distribution_pattern" : "Nationwide and Puerto Rico", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130130", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "0dd6421de423e1d8795a6e1ff22936e89150dad6516861552062e6d3335563dd", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca899c" }, "standardHeader" : { "uuid" : "0ba41616-bdbb-418e-8095-ae4caf1ca394", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1162-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [], "nui" : [], "manufacturer_name" : [ [ "Baxter Healthcare Corporation" ] ], "application_number" : [ [ "NDA016673" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "DEXTROSE" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "DEXTROSE MONOHYDRATE" ] ], "rxcui" : [ [ "309778", "237648" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0338-0017-38", "0338-0017-31", "0338-0017-02", "0338-0017-01", "0338-0017-11", "0338-0017-10", "0338-0017-48", "0338-0023-02", "0338-0023-03", "0338-0017-04", "0338-0017-18", "0338-0017-41", "0338-0017-03", "0338-0023-04" ] ], "generic_name" : [ [ "DEXTROSE MONOHYDRATE" ] ], "spl_id" : [ [ "3a79a5f9-07a9-4ab1-8f27-a3f25878b565" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0338-0017", "0338-0023" ] ], "spl_set_id" : [ [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ] ], "unii" : [] }, "product_quantity" : "105,216 containers", "state" : "IL", "recall_initiation_date" : "20131121", "event_id" : "67092", "product_description" : "5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.", "recalling_firm" : "Baxter Healthcare Corp.", "city" : "Deerfield", "@epoch" : 1424553174.836488, "code_info" : "Lot #: P285288, Exp 11/13", "reason_for_recall" : "Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution.", "distribution_pattern" : "Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140326", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class I", "@id" : "0dfbb4b966edd14b4d5f3f5747936ff6976dd46833fb49a998537ca8124c126c", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca899d" }, "standardHeader" : { "uuid" : "f966decf-5314-4dad-b426-0d8a5cf76697", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-498-2013", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [], "nui" : [], "manufacturer_name" : [ [ "Aurobindo Pharma Limited" ] ], "application_number" : [ [ "ANDA077622" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "LISINOPRIL" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "LISINOPRIL" ] ], "rxcui" : [ [ "197884", "314077", "205326", "314076", "311353", "311354" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "65862-039-99", "65862-042-30", "65862-040-30", "65862-042-99", "65862-039-30", "65862-041-30", "65862-037-01", "65862-037-00", "65862-037-05", "65862-038-99", "65862-038-30", "65862-042-05", "65862-042-01", "65862-042-00", "65862-040-01", "65862-040-00", "65862-040-05", "65862-037-99", "65862-039-01", "65862-039-00", "65862-039-05", "65862-041-05", "65862-041-00", "65862-041-01", "65862-037-30", "65862-040-99", "65862-041-99", "65862-038-05", "65862-038-00", "65862-038-01" ] ], "generic_name" : [ [ "LISINOPRIL" ] ], "spl_id" : [ [ "9ae9f616-bda7-4e88-be8c-58a4ed35c569" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "65862-042", "65862-041", "65862-040", "65862-038", "65862-039", "65862-037" ] ], "spl_set_id" : [ [ "0e6364a4-6d66-4151-8197-d45e2a762895" ] ], "unii" : [] }, "product_quantity" : "1776 bottles", "state" : "NJ", "recall_initiation_date" : "20130409", "event_id" : "65071", "product_description" : "Lisinopril Tablets, USP, 30 mg, Rx only, 100 tablets, NDC 65862-041-01 Manufactured for: Aurobindo Pharma USA Inc. 2400 Route 130 North, Dayton, NJ 08810\nManufactured by: Aurobindo Pharma Limited Hyderabad- 500 072 India", "recalling_firm" : "Aurobindo Pharma USA Inc", "city" : "Plainsboro", "@epoch" : 1424553174.836488, "code_info" : "Lot KP3012001-A Exp.12/13\nLot KP3012002-A Exp.12/13", "reason_for_recall" : "Labeling: Label Error on Declared Strength: Incorrect strength on side display panel of label", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130605", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "0e350ad57402e5532b7d1aa0aa54eb554ffd08dfc216df4b2c834ec098535e18", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f3f60b24f0590ca899e" }, "standardHeader" : { "uuid" : "6a05b955-0311-4ae6-82ef-d708e8b23571", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1425-2014", "openfda" : { "pharm_class_cs" : [ [ "Heparin [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Unfractionated Heparin [EPC]", "Anti-coagulant [EPC]" ] ], "nui" : [ [ "N0000006341", "N0000175474", "N0000175980" ] ], "manufacturer_name" : [ [ "Hospira, Inc." ] ], "application_number" : [ [ "NDA019339" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "HEPARIN SODIUM AND DEXTROSE" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "HEPARIN SODIUM" ] ], "rxcui" : [ [ "1361613", "1361048" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0409-7793-62", "0409-7793-13", "0409-7793-23", "0409-7794-62", "0409-7794-52", "0409-7793-52" ] ], "generic_name" : [ [ "HEPARIN SODIUM" ] ], "spl_id" : [ [ "2996c258-75ce-4254-8197-b2d2326cf215" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0409-7794", "0409-7793" ] ], "spl_set_id" : [ [ "eede8a0c-5ae6-4166-84b3-12081405f08e" ] ], "unii" : [ [ "T2410KM04A" ] ] }, "product_quantity" : "142,152 bags", "state" : "IL", "recall_initiation_date" : "20140606", "event_id" : "68631", "product_description" : "Heparin Sodium in 5% Dextrose Injection, Heparin, 25,000 USP Heparin Units/250 mL (100 USP Heparin Units/mL), 250 mL, Single-Dose Container, Hospira, Inc., Lake Forest, IL 60045 USA,  NDC 0409-7793-62", "recalling_firm" : "Hospira Inc.", "city" : "Lake Forest", "@epoch" : 1424553174.836488, "code_info" : "Lot # 34-811-KL, 36-106-KL, 36-114-KL; Exp. 12/15; 36-101-KL, Exp. 12/15; 37-202-KL, Exp. 1/16; 38-302-KL, Exp. 2/16; 38-305-KL, Exp. 2/16", "reason_for_recall" : "Lack of Assurance of Sterility: Confirmed consumer report of fluid leaking from primary container of bag.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140716", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "0e438e56810cc5d15cf76b14f9c4ea8b5da8562cec90e02c0fe986a9befedd2c", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f4760b24f0590ca899f" }, "standardHeader" : { "uuid" : "9954bd55-66b9-4b6b-a1e9-b60f750cf91e", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1054-2014", "openfda" : { "pharm_class_cs" : [ [ "Cephalosporins [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Cephalosporin Antibacterial [EPC]" ] ], "nui" : [ [ "N0000011161", "N0000175488" ] ], "manufacturer_name" : [ [ "B. Braun Medical Inc." ] ], "application_number" : [ [ "NDA050821" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "CEFEPIME HYDROCHLORIDE AND DEXTROSE" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "CEFEPIME HYDROCHLORIDE" ] ], "rxcui" : [ [ "309056", "309055" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0264-3193-11", "0264-3195-11" ] ], "generic_name" : [ [ "CEFEPIME HYDROCHLORIDE" ] ], "spl_id" : [ [ "968ef12b-cb19-465e-9458-54d1d42e862c" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0264-3195", "0264-3193" ] ], "spl_set_id" : [ [ "57517a0e-ec1b-4605-a7cc-7e3801158ec9" ] ], "unii" : [ [ "807PW4VQE3" ] ] }, "product_quantity" : "18,936 Containers", "state" : "CA", "recall_initiation_date" : "20131015", "event_id" : "66497", "product_description" : "Cefepime for Injection USP and Dextrose Injection USP, in Duplex Drug Delivery System, 1 g in 50 mL duplex container, For IV Use Only, Single Dose, Sterile/Non pyrogenic, Rx Only, B Braun Medical Inc., NDC 0264-3193-11", "recalling_firm" : "B. Braun Medical Inc", "city" : "Irvine", "@epoch" : 1424553174.836488, "code_info" : "Lot H3A744, Exp 01/15", "reason_for_recall" : "Presence of Particulate Matter:  The 1g Cefepime for Injection USP and Dextrose Injection USP lot has been found to contain visible organic particulate matter in a reserve sample unit.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140212", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class I", "@id" : "0f5fe61d5dcc0150bd6f5229164f1969771cb0f02c40806eaebed25c88861408", "initial_firm_notification" : "Press Release", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f4760b24f0590ca89a0" }, "standardHeader" : { "uuid" : "00461da3-34b5-41c0-9078-dd6a8a063c24", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0426-2015", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [], "nui" : [], "manufacturer_name" : [ [ "Baxter Healthcare Corporation" ] ], "application_number" : [ [ "NDA016673" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "DEXTROSE" ] ], "route" : [ [ "INTRAVENOUS" ] ], "substance_name" : [ [ "DEXTROSE MONOHYDRATE" ] ], "rxcui" : [ [ "309778", "237648" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0338-0017-38", "0338-0017-31", "0338-0017-02", "0338-0017-01", "0338-0017-11", "0338-0017-10", "0338-0017-48", "0338-0023-02", "0338-0023-03", "0338-0017-04", "0338-0017-18", "0338-0017-41", "0338-0017-03", "0338-0023-04" ] ], "generic_name" : [ [ "DEXTROSE MONOHYDRATE" ] ], "spl_id" : [ [ "1755dc8f-2d4f-41c7-890a-ea5cf7763fc3" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0338-0017", "0338-0023" ] ], "spl_set_id" : [ [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ] ], "unii" : [] }, "product_quantity" : "48,874", "state" : "IL", "recall_initiation_date" : "20150318", "event_id" : "70770", "product_description" : "5% Dextrose Injection, USP, 1000mL in VIAFLEX Plastic Container, Rx only, Manufactured by Baxter Healthcare Corp., North Cove, North Carolina Facility Highway 221 North, Marion, NC 28752 for Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL 60015. NDC 0338-0017-04", "recalling_firm" : "Baxter Healthcare Corp.", "city" : "Deerfield", "@epoch" : 1428088411.295797, "code_info" : "Lot #: C926899, Exp 7/31/2015", "reason_for_recall" : "Lack of Assurance of Sterility. Complaints were receive of missing closures and/or leaks which may compromise product sterility.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20150401", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "3939ddc26a1598bad3cf502ac0a2cfd62c91e62ac45e66f13339191a3a29d9a1", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f4760b24f0590ca89a1" }, "standardHeader" : { "uuid" : "dcdbd6d8-a9fc-4445-90df-f5737a3bf2af", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1611-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [], "nui" : [], "manufacturer_name" : [ [ "AbbVie Inc." ] ], "application_number" : [ [ "NDA020725" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "CREON" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "PANCRELIPASE LIPASE", "PANCRELIPASE AMYLASE", "PANCRELIPASE PROTEASE" ] ], "rxcui" : [ [ "863841", "863836", "1373327", "863829", "1373325", "855499", "1113042", "855503", "1113046", "855495" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0032-1206-56", "0032-3016-50", "0032-1224-07", "0032-1212-01", "0032-1203-64", "0032-1224-46", "0032-1212-07", "0032-3016-13", "0032-1203-70", "0032-1212-46", "0032-1206-01", "0032-1224-01", "0032-3016-28", "0032-1206-07" ] ], "generic_name" : [ [ "PANCRELIPASE" ] ], "spl_id" : [ [ "3885d979-489b-1335-2fe0-1c848c4bc061" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0032-1212", "0032-1206", "0032-3016", "0032-1224", "0032-1203" ] ], "spl_set_id" : [ [ "073201aa-556d-4a70-918e-84e9616fd88d" ] ], "unii" : [] }, "product_quantity" : "18,021 Bottles", "state" : "IL", "recall_initiation_date" : "20140915", "event_id" : "69285", "product_description" : "CREON (pancrelipase) Delayed-Release Capsules, Lipase 24,000 USP Units, 250 Capsule Bottles, Rx Only. Marketed by: AbbVie Inc., North Chicago, IL 60064, Product of Germany. NDC 0032-1224-07.", "recalling_firm" : "AbbVie Inc", "city" : "North Chicago", "@epoch" : 1424553174.836488, "code_info" : "Lot #: 1020156; Expiry: 3/31/2016", "reason_for_recall" : "Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000.", "distribution_pattern" : "US: Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20141007", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "393f8917378ebd53199c5ac4a742f667312e72ea42ed82258f0977193b2c9d23", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f4760b24f0590ca89a2" }, "standardHeader" : { "uuid" : "cb19f165-d047-4967-a5a7-1e2a1c865aca", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-425-2013", "openfda" : { "pharm_class_cs" : [ [ "Thyroxine [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "l-Thyroxine [EPC]" ] ], "nui" : [ [ "N0000007632", "N0000175945" ] ], "manufacturer_name" : [ [ "Pfizer Laboratories Div Pfizer Inc" ] ], "application_number" : [ [ "NDA021301" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "LEVOXYL" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "LEVOTHYROXINE SODIUM" ] ], "rxcui" : [], "pharm_class_pe" : [], "package_ndc" : [ [ "60793-854-01", "60793-853-01", "60793-855-10", "60793-856-01", "60793-857-10", "60793-860-10", "60793-852-01", "60793-858-01", "60793-850-01", "60793-855-01", "60793-859-10", "60793-851-10", "60793-854-10", "60793-853-10", "60793-856-10", "60793-860-01", "60793-857-01", "60793-858-10", "60793-852-10", "60793-850-10", "60793-859-01", "60793-851-01" ] ], "generic_name" : [ [ "LEVOTHYROXINE SODIUM" ] ], "spl_id" : [ [ "08c86bc8-2917-4e56-b87d-1ddb73ce507f" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "60793-860", "60793-858", "60793-859", "60793-854", "60793-855", "60793-856", "60793-857", "60793-850", "60793-851", "60793-852", "60793-853" ] ], "spl_set_id" : [ [ "758588c3-c63e-491b-0aa2-4f50d80cb174" ] ], "unii" : [ [ "Q51BO43MG4" ] ] }, "product_quantity" : "195,201 bottles", "state" : "TN", "recall_initiation_date" : "20130430", "event_id" : "65172", "product_description" : "Levoxyl (levothyroxine sodium) tablets, USP, 100 mcg, packaged in a) 100-count bottles (NDC 60793-854-01) and b) 1000-count bottles (NDC 60793-854-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620", "recalling_firm" : "King Legacy, a wholly owned subsidiary of Pfizer", "city" : "Bristol", "@epoch" : 1424553174.836488, "code_info" : "Lot # a) 64341, Exp 04/13;  64928, Exp. 5/13; 65064, Exp. 5/13; 65233, Exp. 7/13; 66162, Exp. 8/13; 66365, Exp. 10/13; and 66677, Exp. 11/13; b) 64342, Exp. 4/13; 64929, Exp. 5/13; 65065, Exp. 5/13; 65234, Exp. 7/13; 65539, Exp. 7/13; 65901, Exp. 8/13; and 66163, Exp. 8/13", "reason_for_recall" : "Subpotent Drug: The products were below specification for potency at the expiry stability point.", "distribution_pattern" : "Nationwide and Puerto Rico", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20130529", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "0fb6a9da32859b28c7935fc8882dc6c6989b5805c558a6b3d2edff50e3da6ae9", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f4760b24f0590ca89a3" }, "standardHeader" : { "uuid" : "630bb217-da45-4d15-890e-79c4a4f69276", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-0232-2015", "openfda" : { "pharm_class_cs" : [ [ "Glycopeptides [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Glycopeptide Antibacterial [EPC]" ] ], "nui" : [ [ "N0000175491", "N0000007889" ] ], "manufacturer_name" : [ [ "Watson Laboratories, Inc." ] ], "application_number" : [ [ "ANDA065510" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "VANCOMYCIN HYDROCHLORIDE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "VANCOMYCIN HYDROCHLORIDE" ] ], "rxcui" : [ [ "313571", "313570" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "0591-3560-15", "0591-3561-15", "0591356015" ] ], "generic_name" : [ [ "VANCOMYCIN HYDROCHLORIDE" ] ], "spl_id" : [ [ "5422685c-f6f5-4c20-95e7-d75a43e738ad" ] ], "upc" : [ [ "305913560154" ] ], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [], "product_ndc" : [ [ "0591-3561", "0591-3560" ] ], "spl_set_id" : [ [ "f04711a7-652e-427d-a7f5-65d4a1c3cae4" ] ], "unii" : [ [ "6Q205EH1VU" ] ] }, "product_quantity" : "26,663 cartons", "state" : "NJ", "recall_initiation_date" : "20140825", "event_id" : "69553", "product_description" : "Vancomycin Hydrochloride Capsule, USP, 125 mg, 20 count blister pack, Rx Only, Mfd. for: Watson Pharma. Inc. Parsippany, NJ 07054 USA, Mfd. by: Patheon Pharmaceuticals Inc. Cincinnati, OH 45237 USA ---- NDC 0591-3560-15 UPC Code 3-0591356015-4", "recalling_firm" : "Actavis Inc", "city" : "Parsippany", "@epoch" : 1424553174.836488, "code_info" : "3103681, exp Aug 2014,\n3104886, exp Oct 2014,\n3105836, exp Dec 2014, and\n3106650, exp Dec 2014", "reason_for_recall" : "Subpotent Drug", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20141105", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "1066b2b737334c528aeae2da4a373d20c0f5a6356b6b9f2af094b886da1c9972", "initial_firm_notification" : "Letter", "recall_area" : [ "Nationwide" ] }
{ "_id" : { "$oid" : "55897f4760b24f0590ca89a4" }, "standardHeader" : { "uuid" : "f00350c9-eb8b-49db-af4c-8770000ba637", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-1584-2014", "openfda" : { "pharm_class_cs" : [], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Vitamin K Antagonist [EPC]" ] ], "nui" : [ [ "N0000175476", "N0000175964" ] ], "manufacturer_name" : [ [ "Taro Pharmaceuticals U.S.A., Inc." ] ], "application_number" : [ [ "ANDA040301" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "WARFARIN SODIUM" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "WARFARIN SODIUM" ] ], "rxcui" : [ [ "855332", "855288", "855344", "855318", "855324", "855302", "855338", "855312", "855296" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "51672-4027-7", "51672-4027-3", "51672-4027-0", "51672-4027-1", "51672-4029-7", "51672-4029-0", "51672-4029-1", "51672-4029-3", "51672-4032-0", "51672-4032-1", "51672-4032-3", "51672-4033-7", "51672-4032-7", "51672-4034-3", "51672-4034-0", "51672-4034-1", "51672-4035-3", "51672-4035-1", "51672-4035-0", "51672-4033-1", "51672-4030-7", "51672-4030-3", "51672-4030-0", "51672-4030-1", "51672-4031-3", "51672-4031-1", "51672-4031-0", "51672-4031-7", "51672-4033-0", "51672-4033-3", "51672-4028-1", "51672-4028-0", "51672-4028-3", "51672-4028-7" ] ], "generic_name" : [ [ "WARFARIN SODIUM" ] ], "spl_id" : [ [ "ffa3ce67-3269-4938-a461-4245782d1e4b" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Vitamin K Inhibitors [MoA]" ] ], "product_ndc" : [ [ "51672-4033", "51672-4032", "51672-4031", "51672-4030", "51672-4028", "51672-4029", "51672-4035", "51672-4034", "51672-4027" ] ], "spl_set_id" : [ [ "8ad881e0-ca41-42ad-9d7d-eb85b3a30af0" ] ], "unii" : [ [ "5Q7ZVV76EI" ] ] }, "product_quantity" : "1396 Bottles", "state" : "NY", "recall_initiation_date" : "20140825", "event_id" : "69075", "product_description" : "Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.", "recalling_firm" : "Taro Pharmaceuticals U.S.A., Inc.", "city" : "Hawthorne", "@epoch" : 1424553174.836488, "code_info" : "Lot #: 149400, Expiry: January 2016; \nLot #: 149649, Expiry: January 2016.", "reason_for_recall" : "Failed Content Uniformity Specifications.", "distribution_pattern" : "United States including: OH, HI, NH, MS, IL, TX, CA.", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140924", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class III", "@id" : "397f100ee49b43c8ce0016e9a681805b078661d1865891757fc528d44bf1fe34", "initial_firm_notification" : "Letter", "recall_area" : [ "California", "Hawaii", "Illinois", "Mississippi", "New Hampshire", "Ohio", "Texas" ] }
{ "_id" : { "$oid" : "55897f4760b24f0590ca89a5" }, "standardHeader" : { "uuid" : "390ed62e-e6c5-4733-9315-94e953740009", "source" : "UNKNOWN", "accessLabel" : "UNCLASSIFIED", "modelName" : "fda_enforcement", "modelVersion" : "1.1" }, "recall_number" : "D-737-2014", "openfda" : { "pharm_class_cs" : [ [ "Dihydropyridines [Chemical/Ingredient]" ] ], "original_packager_product_ndc" : [], "pharm_class_epc" : [ [ "Dihydropyridine Calcium Channel Blocker [EPC]" ] ], "nui" : [ [ "N0000175421", "N0000007556", "N0000000069" ] ], "manufacturer_name" : [ [ "Greenstone LLC" ] ], "application_number" : [ [ "NDA019684" ] ], "product_type" : [ [ "HUMAN PRESCRIPTION DRUG" ] ], "brand_name" : [ [ "NIFEDIPINE" ] ], "route" : [ [ "ORAL" ] ], "substance_name" : [ [ "NIFEDIPINE" ] ], "rxcui" : [ [ "198035", "198034", "198036" ] ], "pharm_class_pe" : [], "package_ndc" : [ [ "59762-6690-8", "59762-6692-8", "59762-6691-8", "59762-6690-3", "59762-6691-5", "59762-6692-3", "59762-6691-3", "59762-6690-5" ] ], "generic_name" : [ [ "NIFEDIPINE" ] ], "spl_id" : [ [ "2134f93f-cbfd-40aa-819d-54ade221136c" ] ], "upc" : [], "is_original_packager" : [ [ true ] ], "pharm_class_moa" : [ [ "Calcium Channel Antagonists [MoA]" ] ], "product_ndc" : [ [ "59762-6692", "59762-6691", "59762-6690" ] ], "spl_set_id" : [ [ "5a9b3e3a-fb7a-4cda-892f-c7232c73323c" ] ], "unii" : [ [ "I9ZF7L6G2L" ] ] }, "product_quantity" : "21600 tablets", "state" : "NJ", "recall_initiation_date" : "20131101", "event_id" : "66760", "product_description" : "Nifedipine, extended-release tablets, 90mg 100 count blister pack,  Rx only, Distributed by: GREENSTONE LLC, Pespack, NJ,07977, NDC 59762-6692-8", "recalling_firm" : "Greenstone Llc", "city" : "Peapack", "@epoch" : 1424553174.836488, "code_info" : "V110079", "reason_for_recall" : "Labeling: Incorrect or Missing Lot and/or Exp Date: Greenstone LLC is recalling  Nifedipine Extended Release tablets (90mg). The expiration date on the package is 48 months instead of 36 months.", "distribution_pattern" : "Nationwide", "status" : "Ongoing", "product_type" : "Drugs", "country" : "US", "report_date" : "20140122", "voluntary_mandated" : "Voluntary: Firm Initiated", "classification" : "Class II", "@id" : "1175b9b9f9c7420132cf6d9bced6b0324e291dbea96b94740198a99097e5dcaf", "initial_firm_notification" : "Telephone", "recall_area" : [ "Nationwide" ] }
